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ABSTRACT 
 
Kelsey Marie Gray: Survival Motor Neuron protein interaction partners 
in Drosophila melanogaster 
(Under the direction of A. Gregory Matera) 
 
Spinal Muscular Atrophy (SMA) is a neuromuscular disorder that results from 
biallelic loss-of-function mutations in the human survival motor neuron 1 (SMN1) gene. 
Tissue-specific and housekeeping functions have been ascribed to SMN; however, their 
relevance to SMA pathology is not well understood. We generated transgenic Drosophila 
melanogaster that express only flag-tagged wild-type SMN. Our objective is to 
characterize novel protein-protein interactions of SMN. We collected embryos and 
analyzed Flag-purified lysates by mass spectrometry. We identified Flag-SMN along 
with other known interactors such as the Sm proteins and the Gemins. 
We also identified Slmb, SkpA, and Cullin 1 as being highly enriched in Flag-
SMN samples as compared to the control sample. Together, these proteins comprise the 
SCFSlmb E3 ubiquitin ligase. These interactions were verified in Drosophila S2 cells and 
human cells. In vitro experiments revealed Slmb and SMN can directly interact.  
Identification of a putative Slmb degron in the self-oligomerization domain of SMN led 
us to generate a serine to alanine mutation that stabilizes full length and truncated SMN, 
with strongest effects on SMN with poor self-oligomerization capability. This same point 
mutation decreases SMN’s interaction with Slmb, demonstrating the putative Slmb 
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degron is indeed mediating degradation of SMN. Finally, expression of truncated SMN 
stabilized by the mutation modifies viability of a mild SMA mouse model. 
We identified additional protein interactions of SMN with CG2941, nucleosome 
assembly protein 1 (Nap1), and Bendless (Ben). Each of these interactions was verified in 
cell culture or using antibodies generated specifically for the protein of interest. 
Preliminary investigation of CG2941 has revealed it is an essential gene that produces 
protein that localizes to both the nucleus and the cytoplasm. 
We have examined SMN protein interactions in the context of developing 
Drosophila melanogaster embryos, with follow-up studies in mouse, and human systems. 
When SMN is unable to self-oligomerize, the Slmb degron is highly accessible, and thus 
SMN is degraded. SMN also interacts with previously unknown partners that may be 
relevant to SMA pathology. This work elucidates a disease-relevant mechanism where 
SMN levels are regulated by self-multimerization and identifies candidate proteins for 
further study of the molecular mechanisms underlying SMA. 
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CHAPTER I: Introduction 
 
Spinal Muscular Atrophy 
Spinal muscular atrophy (SMA) is a common neuromuscular disorder that is the 
most prevalent genetic cause of infant mortality (Pearn 1980). SMA has a carrier 
frequency of 1 in 50 and an incidence rate of 1 in 6,000-10,000 (Ogino et al. 2002).  The 
disease presents clinically as the degeneration of motor neurons in the anterior horn of the 
spinal cord (Crawford and Pardo 1996). Without stimulation from the neuron, the 
proximal muscles atrophy, leading to subsequent loss of motor function, and ultimately 
symmetrical paralysis. Since the timing of the onset of symptoms and their severity can 
vary, SMA has historically been classified into subtypes (Ogino S 2004). More recently, 
clinicians have recognized that SMA is better characterized as a continuous spectrum 
disorder, ranging from severe (prenatal onset) to nearly asymptomatic (Tiziano et al. 
2013) 
While there are several different ways to classify SMA, one of the most 
commonly used systems separates SMA cases into three types based on the severity of 
the phenotype, which is determined by the age of onset and the level of maximum motor 
function achieved by the patient (Ogino S 2004). Type I SMA is the most common form 
of the disease, affecting ~60% of SMA patients (Nicole et al. 2002; Ogino S 2004). Type 
I SMA, alternatively known as Werdnig-Hoffman disease, is also the most severe form. 
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Symptoms begin to appear as early as in utero and are clearly detectable during the first 6 
months of life (Wee et al. 2010; Prior 2010). Affected infants experience progressive 
muscle weakness, which correlates with a reduced ability to swallow. These infants most 
frequently die from complications such as progressive and restrictive respiratory failure 
by 2 years of age (Kolb and Kissell 2015).  Type II SMA is less severe with symptom 
onset occurring between 6 and 18 months of age.  These children experience 
developmental motor delays and are unable to stand or walk, although they can sit 
unsupported.  The lifespan of type II patients can vary from 2 to 30 years, with death 
usually occurring as a result of respiratory infections.  SMA type III, also known as 
Kugelberg-Welander disease, is the mildest form with an age of onset after 2 years.  Most 
type III patients are able to stand and walk, but often need to use a wheelchair in 
adulthood due to muscle weakness. Many type III patients have a normal life expectancy 
since the disease progress is slow. 
SMA Genetic Etiology 
In 1990, linkage analysis was used to map the SMA-causing gene to chromosome 
5q11.2-13.3 in several affected families (Brzustowicz et al. 1990; Melki et al. 1990). 
Lefebvre et al. (1995) discovered a gene in that chromosomal region, survival of motor 
neuron 1 (SMN1), that was identified to be the causative gene in SMA (Bussaglia et al. 
1995; Rodrigues et al. 1995; van der Steege et al. 1995; Chang et al. 1997). At this time, 
it was determined that over 95% of SMA patients have deletions of SMN1 (Lefebvre et 
al. 1995; Campbell et al. 1997). 
Further investigation of the 5q chromosome region revealed the presence of at 
least two SMN paralogs in most people (Fig. 1.1). There is a 500 kb inverted duplication 
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located at 5q11-13 that resulted in a telomere-proximal copy (SMN1) and a centromere-
proximal copy (SMN2) of the SMN gene (Lefebvre et al. 1995). Five base pair differences 
distinguish the two SMN copies at the nucleotide level, but each of these nucleotide 
changes leave the amino acid sequence of the protein unchanged. The nucleotide 
difference that affects the functionality of the proteins produced by each of the genes is a 
change from C to T in exon 7 of the SMN2 gene (Lorson et al. 2010). This change affects 
splicing and results in the exclusion of exon 7 (SMNΔ7) in ~90% of the SMN2 transcripts 
(Fig. 1.1).  This SMNΔ7 transcript encodes a truncated and unstable protein. The last 16 
amino acids of SMN are replaced in SMNΔ7 by four amino acids, EMLA, encoded by 
exon 8. 
Current estimates suggest the remaining ~10-15% of transcripts are full length 
and encode protein that is fully functional and indistinguishable from that produced by 
SMN1 (Lorson et al. 1999; Monani et al. 1999; Lorson et al. 2000). Thus, both SMN1 and 
SMN2 contribute to total cellular levels of SMN protein. 
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Figure 1.1. SMN1 and SMN2 are found on human chromosome five. SMN2 cannot fully 
compensate for loss of SMN1, but is the most significant modifier of the disease 
phenotype. A base change from C to T in the SMN2 gene results in the exclusion of exon 
7 and production of a truncated and unstable protein with the addition of four amino acids 
(EMLA) (Δ7) in ~90% of the transcripts and full-length (FL) protein in ~10% of the 
transcripts.  
 
Complete loss of SMN expression is lethal in all organisms investigated to date 
(Schrank et al. 1997; O’Hearn et al. 2016); therefore, SMA is a disease that arises due to 
hypomorphic reduction in SMN levels (Lefebvre et al. 1995). Although the amount of 
full-length protein produced by SMN2 is not enough to compensate for loss of SMN1, 
SMN2 is sufficient to rescue embryonic lethality (Monani et al. 2000). Studies in SMA 
patients have revealed that decreased levels of functional, full length SMN protein 
correlate with the phenotypic severity of SMA (Lefebvre et al. 1997; Coovert et al. 
1997). These findings contributed to the formulation of a connection between these genes 
and SMA. 
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SMA is a gene dosage disorder with SMN2 being the primary genetic modifier of 
the phenotype.  There is an inverse correlation between the number of SMN2 copies in 
the genome and disease severity (Vitali et al. 1999). Mildly affected patients generally 
have more copies of SMN2 than those with more severe phenotypes. Consistent with this 
observation, levels of SMN protein in cells from SMA type I patients are reduced to 5-
20% of levels in controls (Lefebvre et al. 1997; Vitali et al. 1999). In contrast, type III 
SMA patient cells have SMN levels that are comparable to controls. One potential 
explanation for this finding is that type I SMA is caused by deletions and/or mutations in 
the SMN1 gene, whereas type III SMA results from gene conversion events that convert 
SMN1 to SMN2 (Campbell et al. 1997).  In the latter case, there would be more copies of 
SMN2, since SMN1 was converted, and thus more functional SMN protein. This would 
result in a milder SMA phenotype. While SMA typically results from homozygous 
deletion of SMN1 gene (Lefebvre et al. 1995), a small fraction of SMA patients in all 
three categories of severity have lost one copy of SMN1 and the remaining copy contains 
a missense mutation (Burghes and Beattie 2009). While the genetic etiology of the 
disease is well-established, the molecular role of SMN in the disease is largely unknown. 
Several animal models of SMA, including Drosophila melanogaster, are used to address 
this open question. 
SMN Protein and the SMN Complex 
The SMN1 gene and protein are highly conserved in evolution, with homologs 
found in all major eukaryotic model organisms investigated except S. cerevisiae. The 
human SMN protein is 294 amino acids long and has three well described domains: the 
Gemin2 binding domain, the Tudor domain, which is found in many RNA-binding 
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proteins, and the C-terminal region called the YG box (Fig. 1.2).  The Tudor domain is 
thought to be involved in binding of SMN to Sm proteins (Buhler et al. 1999). The YG 
box is the most well conserved region in the protein and is involved in SMN self-
oligomerization (Lorson et al. 1998). Interestingly, primates are the only species that 
have more than one copy of the SMN gene, and only humans have the C to T base change 
that defines the SMN2 gene. Researchers have failed to detect any SMNΔ7 mRNA in our 
closest relative, the chimpanzee (DiDonato et al. 1997; Rochette et al. 2001).   
 
Figure 1.2. Major domains in the SMN protein. Survival of motor neuron protein is 
conserved from yeast to humans and contains three functional domains. The SMN protein 
has an N-terminal domain that is important for binding to Gemin2, a member of the 
canonical SMN complex. The tudor domain, which is present in many RNA binding 
proteins, interacts with Sm proteins. The YG box mediates SMN self-oligomerization. 
This domain forms a glycine zipper structure, similar to that seen in transmembrane 
proteins. Figure modified from the thesis of Kavita Praveen (Praveen, 2012) using YG 
Box structure from Martin et al. 2012. 
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Consistent with its function in the essential process of snRNP biogenesis, SMN is 
ubiquitously expressed (Coovert et al. 1997; Burlet et al. 1998) and localizes to the 
cytoplasm as well as the nucleus.  In the cytoplasm, SMN is diffuse, whereas SMN is 
found in nuclear foci called Cajal bodies in the nuclei of most tissues (Carvalho et al. 
1999).  Cajal bodies contain high levels of snRNPs, small nucleolar ribonucleoproteins 
(snoRNPs), small Cajal body specific ribonucleoproteins (scaRNPs) as well as other 
proteins involved in RNP metabolism (reviewed in Matera et al. 2006).   
SMN is found as part of a large multimeric complex consisting of SMN, the 
Gemins, and Unrip in the cytoplasm (Charroux et al. 1999; Charroux et al. 2000; Baccon 
et al. 2002; Gubitz et al. 2002; Pellizzoni et al. 2002; Grimmler et al. 2005; Carissimi et 
al. 2006) (Fig. 1.3). The entire SMN complex is required for proper snRNP assembly in 
vivo. SMN and Gemin2 alone are not sufficient to restore RNP assembly activity in 
Xenopus egg extracts immunodepleted for these proteins (Meister et al. 2001). A number 
of additional studies have confirmed this requirement for the other members of the SMN 
complex (Meister et al. 2001; Feng et al. 2005; Shpargel et al. 2005; Battle et al. 2006; 
Ogawa et al. 2007). It is possible that the other SMN complex members may be involved 
in snRNP-independent functions of SMN (Zhang et al. 2006; Walker et al. 2008; Todd et 
al. 2010).  
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Figure 1.3. Comparison of core SMN complex members in human (mammal) and 
Drosophila. Only verified members are shown in each representation and the 
stoichiometry is not intended to reflect true relative amounts of protein. The human SMN 
complex includes Gemin2/3/4/5/6/7/8 and Unrip/STRAP. Drosophila has a lesser verified 
SMN complex, consisting only of Gemin2/3 and Unrip. The Drosophila homolog of 
Gemin5, rig, is likely a member of the complex. However, rig has not been definitively 
shown to play a role in snRNP biogenesis. Figure from Greg Matera, unpublished. 
        
While orthologs of Gemin2 can be identified in all species, the other Gemins are 
not as well conserved (Fig. 1.3). A bioinformatic investigation to identify Gemin 
homologs suggested that Gemins 3 and 5 are the most ancestral Gemins in the complex 
(Kroiss et al. 2008). Putative homologs of Gemins 4, 6, 7, and 8 were only found in 
animals at the time, suggesting they are newer additions to the complex. Both Dipterans 
that were analysed, D.melanogaster and A.gambiae, seemed to have only Gemins 2, 3 
and 5 (Fig. 1.3).  
HeLa cells require SMN and Gemins 2, 3, 4 and 5 for snRNP assembly (Feng et 
al. 2005; Shpargel et al. 2005). A minimal SMN complex, consisting of SMN and 
Gemin2 only, is sufficient for assembly of Sm proteins onto snRNAs in vitro (Kroiss et 
al. 2008). Therefore, while other SMN complex members may not be essential for the 
assembly reaction, they enhance snRNP assembly in vivo. These enhancement functions 
include improving specificity of assembly of the Sm ring on the snRNA and speeding up 
the reaction. As previously mentioned, the SMN complex is associated with the Sm-
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snRNA complex throughout the cytoplasmic phase of assembly (Massenet et al. 2002) 
and is also important for re-import of the immature snRNP into the nucleus (Narayanan et 
al. 2002; Narayanan et al. 2004). This presents the possibility that Gemins have functions 
in steps following the assembly of Sm proteins onto snRNAs. 
The Gemins are very structurally different, and the precise function of most of 
them in the SMN complex is not clear. However, there are suggestions for the functions 
of several of them. For example, Gemin2 has been reported to stabilize SMN by 
enhancing SMN self-association through the N-terminal Gemin2 binding domain (Ogawa 
et al. 2007). Additionally, Gemin2 binds a pentamer of the Sm proteins D1, D2, E, F and 
G directly, as visualized in a crystal structure of Gemin2 with the Gemin2-binding 
domain of SMN (Zhang et al. 2011). Gemin3 contains a DEAD box domain with 
potential helicase activity; therefore, Gemin3 may perform the ATP dependent step of the 
assembly reaction (Charroux et al. 1999). Gemin5 has been shown to bind snRNAs 
directly, which could contribute to distinguishing them from other RNAs (Battle et al. 
2006). This mechanism provides specificity to the assembly reaction (Battle et al. 2006). 
Gemins 6 and 7 form a heterodimer that is similar to the structure created by 
heterodimers of SmB/SmD3 and SmD1/SmD2 (Ma et al. 2005). Gemins 6 and 7 also 
interact with a subset of Sm proteins. It has been suggested that Gemins 6 and 7 act as 
“place holders” for SmB/SmD3 in the Sm protein pentamer that binds Gemin2 (Zhang et 
al. 2011) before assembly onto the snRNA. Functions have not been assigned to the 
remaining members of the SMN complex.  
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SMN Function 
A role of SMN in RNA metabolism was the first suggested cellular function (Liu 
et al. 1996). This was determined due to the observation that SMN protein can associate 
with the RNA binding domain of hnRNP U, an RNA binding protein. The role of SMN in 
RNA metabolism was bolstered when, in 1997, Liu et al. showed that SMN, along with 
Gemin2, co-purified with a set of proteins that bind to uridine-rich small nuclear 
ribonucleoproteins (U-snRNPs). These proteins are called Sm proteins. Fischer et al. 
(1997) determined the functional significance of the interaction by using Xenopus 
oocytes to show that SMN and Gemin2 were involved in an early step in spliceosomal U-
snRNP biogenesis. These data were corroborated in 2001 by Meister et al. who showed 
that the SMN complex was required for in vivo assembly of Sm proteins onto U-snRNAs.  
snRNP Biogenesis 
SMN is expressed in all tissues of animals (Matera and Wang 2014; Tripsianes et 
al. 2011; Li et al. 2014). The best-characterized function for the ubiquitous SMN protein 
is in the assembly of Sm-class snRNPs. Sm-class snRNPs are made up of uridine-rich 
snRNAs, non-coding RNAs that perform diverse roles in RNA metabolism (Mattaj et al. 
1993; Tern and Steitz, 1997). Sm-class snRNPs also contain several specific proteins that 
are unique to each snRNA and a set of 7 common Sm proteins. 
The Sm-class snRNPs form the core components of the spliceosome. Two distinct 
classes of spliceosomes exist: the ‘major’ spliceosome and the ‘minor’ spliceosome 
(Levine and Durbin 2001). The ‘major’ spliceosome is responsible for over 99% of intron 
splicing in the human genome while the ‘minor’ spliceosome removes the remaining 
<1% of introns. Based on this information, it is reasonable to predict that the cell would 
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require higher levels of the components of the major-class than there are of the minor-
class. Indeed, the major-class snRNAs are ~100 fold more abundant than the snRNAs 
that make up the minor-class spliceosome (Zieve and Sauterer 1990). U1, U2, U4 and U6 
snRNAs make up the major-class and U11, U12, U4atac and U6atac snRNAs comprise 
the minor-class (Levine and Durbin 2001). The U5 snRNA is shared by both 
spliceosomes (Patel and Steitz 2003).  
 
Figure 1.4. Overview of the mammalian snRNP biogenesis pathway. A. After snRNA 
transcription by RNA polymerase II, the pre-snRNA is bound by PHAX to create the 
export complex and this complex often enters the Cajal body. PHAX then recruits CRM1 
and Ran to export the pre-snRNA out to the cytoplasm. In the cytoplasm, the export 
complex disassembles. Sm core assembly occurs when the snRNA is loaded with a seven 
membered ring of Sm proteins by the SMN complex. The pre-snRNA is further modified 
by methylation of the 7-methyl guanosine (m7G) cap to a trimethylguanosine (m3G) cap 
and trimming of the 3’ end of the snRNA by an exonuclease (EXO). B. The snRNA is 
imported into the nucleus, along with the SMN complex, by Snurportin (SPN1) and 
 12 
Importin β, where it localizes to the Cajal body. There, the snRNA binds other proteins 
and acquires further modifications. Figure from Raimer, Gray, and Matera 2016. 
 
The life cycle of the Sm-class U-snRNAs takes place in both the cytoplasm and 
the nucleus (Fig. 1.4). Sm-class snRNAs are transcribed by RNA polymerase II and 
contain additional nucleotides at the 3’ end and a monomethylated m7GpppG (m7G) cap 
structure at the 5’ end (Cougot et al. 2004) (Fig 1.4A). After 3’ end processing to remove 
the extraneous nucleotides, pre-snRNA transcripts are exported from the nucleus by a set 
of factors that includes the cap-binding complex (CBP80 and CBP20), the snRNA-
specific export adaptor phosphorylated adaptor RNA export (PHAX), and arsenite 
resistance 2 (ARS2) (Hallais et al. 2013; Frey et al. 1995; Frey et al. 1999; Ohno et al. 
2000; Frey et al. 2001; Suzuki et al. 2010). These proteins link the 5’ cap of the snRNA 
to the nuclear export receptor chromosome region maintenance 1 (CRM1/Exportin1). 
This entire complex interacts with nuclear pore proteins to promote export to the 
cytoplasm (Fornerod et al. 1997). The snRNA nuclear export complex dissociates upon 
phosphorylation of PHAX in the cytoplasm (Kitao et al. 2008; Ohno et al. 2000). The 
SMN protein complex regulates the entire cytoplasmic phase of the snRNP cycle (Fig. 
1.4B). Specific phases of snRNP biogenesis in the cytoplasm regulated by SMN include 
Sm core assembly, trimethylguanosine (TMG) cap formation, and Snurportin1 binding to 
the TMG cap structure. 
The SMN complex serves as a scaffold for Sm core assembly upon which Sm 
proteins and snRNA are assembled (Fig. 1.4B). The seven Sm proteins are called 
SmB/B’, SmD1, SmD2, SmD3, SmE, SmF, and SmG. In an adenosine triphosphate 
(ATP) dependent reaction, these proteins are assembled onto a conserved motif of the 
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pre-snRNA called the ‘Sm-site’ to form a ring (Kambach et al. 1999; Will et al. 2001; 
Meister et al. 2002; Pellizzoni et al. 2002; Yong et al. 2004; Golembe et al. 2005; 
Paushkin et al. 2002). Assembly of the Sm core not only stabilizes the snRNA by 
protecting it from nucleases, but also is required for downstream RNA-processing steps. 
The Sm proteins are delivered to the SMN complex due to the activity of the 
protein arginine methyltransferase 5 (PRMT5) complex, consisting of PRMT5, pICln, 
and WD45 (Mep50) (Brahms et al. 2000; Brahams et al. 2001; Friesen et al. 2001; 
Meister et al. 2001; Friesen et al. 2002). The PRMT5 complex symmetrically 
dimethylates C-terminal arginine residues within SmB, SmD1, and SmD3 (Meister et al. 
2001; Friesen et al. 2001). These methylation marks enhance the interaction between the 
Sm proteins and SMN. In Drosophila, Sm protein methylation is not necessary for 
snRNP assembly (Gonsalvez et al. 2008). Thus, while many of the biochemical 
properties of snRNP biogenesis are conserved between flies and mammals, this is an 
important caveat to consider. 
Gemin5 is thought to be the component of the SMN complex responsible for 
recognition of Sm-class snRNAs (Yong et al. 2010). Although the assembly of the Sm 
core onto the snRNA can occur spontaneously and non-specifically in vitro, the SMN 
complex is thought to provide specificity, to avoid assembly of Sm cores onto non-target 
RNAs (Pellizzoni et al. 2002; Yong et al. 2010), and to accelerate formation of the final 
product from kinetically trapped intermediates (Chari et al. 2008). The role SMN plays in 
snRNP assembly is crucial because without Sm core assembly snRNPs are incapable of 
nuclear re-import. This would prevent their participation in active splicing within the 
nucleus.  
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Following Sm-core assembly, an RNA methyltransferase called 
trimethylguanosine synthase (TGS1) is recruited to the m7G cap (Mouaikel et al. 2002; 
Verheggen et al. 2002). The SMN complex does not immediately dissociate from the 
RNA after Sm-core assembly, suggesting that SMN may play a role in the recruitment of 
TGS1 to the complex (Mouaikel et al. 2003). Additionally, it has been shown that TGS1 
directly interacts with SMN both in vivo and in vitro supporting the role of SMN in 
recruitment. TGS1 hypermethylates the cap to form a 2,2,7-trimethylguanosine (TMG) 
cap structure. A properly assembled Sm core is required for this process as well as for 3’- 
end maturation (Mouaikel et al. 2002; Mattaj 1986; Neuman de Vegvar and Dahlberg 
1990).  
Once the cytoplasmic phase of snRNP biogenesis is complete, Importinβ (Impβ) 
binds the import adaptor Snurportin 1 (SPN1) that attaches to the TMG cap and imports 
the partially assembled pre-snRNP, along with the SMN complex, back into the nucleus 
(Fig. 1.4B) (Palacios et al. 1997; Huber et al. 1998; Narayanan et al. 2004). Interaction 
between SMN and Impβ, and observations that snRNP import is defective in the presence 
of some SMN mutations, indicate that SMN may also function in facilitating snRNA 
nuclear import (Narayanan et al. 2002; Narayanan et al. 2004). This means it is possible 
that SMN plays a role in every stage of snRNP development, in both the cytoplasm and 
the nucleus. 
The process of snRNP assembly and import is rapid, taking place in 
approximately one hour, as shown by pulse chase (Gonsalvez et al. 2007). Once in the 
nucleus, pre-snRNPs localize to Cajal bodies, are released from the SMN complex, 
further modified, and bound by other snRNP-specific proteins. Mature snRNPs can be 
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stored in nuclear domains called speckles, where snRNPs are thought to be kept while not 
participating in splicing (Sleeman and Lamond 1999; Fakan 1994). snRNPs may also 
localize to active transcription sites in perichromatin fibrils where they actively 
participate in splicing. 
 
Two spliceosomal snRNAs, U6 and U6atac, have not been discussed thus far and 
do not follow the same assembly pathway as the others.  U6 and U6atac are transcribed 
by RNA polymerase III and acquire a γ-monomethyl cap after transcription. They bound 
by seven Sm-like (Lsm) proteins (Lsm2-Lsm8) (Achsel et al. 1999), and are referred to as 
“Lsm-class” snRNAs. These Lsm proteins are used in place of the Sm proteins that 
assemble around the other snRNAs. The assembly of U6 and U6atac is thought to occur 
entirely within the nucleus and appears to be independent of SMN. 
snRNP independent functions of SMN 
Although snRNP biogenesis remains by far the most well established function of 
SMN, the protein has also been implicated in other global and tissue-specific roles. For 
example, SMN has been reported to influence the activity of a viral transcription activator 
(Strasswimmer et al. 1999). SMN has also been suggested to interact with RNA helicase 
A and RNA polymerase II (Pellizzoni et al. 2001), invoking the possibility that it may 
function in transcriptional regulation. Further evidence supporting this function of SMN 
was provided when Zhao et al. (2015) demonstrated that SMN binds the RNA 
polymerase II C-terminal domain after it is symmetrically dimethylated on arginine 
residue R1810 (Fig. 1.5). SMN also interacts with Senataxin (SETX), a helicase that 
unwinds R-loops around transcription termination sites (Suraweera et al. 2009), allowing 
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XRN2 exonuclease to be recruited, thereby contributing to transcription termination 
(Skourti-Stathaki et al. 2011). 
 
Figure 1.5. The potential role of SMN in transcriptional regulation. A. SMN interaction 
with R1810me2s on the C-terminal domain (CTD) of RNA polymerase II (RNAPII) 
stabilizes SETX, an RNA/DNA helicase, interaction with the CTD. SETX allows the 
spliceosome to access and splice the RNA by preventing R-loop formation. B. Following 
reduction of SMN or loss of R1810 methylation, SETX is not recruited as efficiently 
resulting in an increase in R-loop formation. RNAPII accumulates at the transcription 
termination site. Figure from Raimer, Gray, and Matera 2016. 
 
A number of observations have raised the possibility of neuron and muscle 
specific roles for SMN. One such function is in regulating actin dynamics via SMN’s 
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connections to Profilin and Plastin3, which are actin bundling proteins (Giesemann et al. 
1999; Sharma et al. 2005; Oprea et al. 2008; Ackermann et al. 2013). This function of 
SMN may be the primary cause for defects observed in SMA, such as problems with 
endocytosis at the synapse (Custer and Androphy 2014; Dimitriadi et al. 2016; 
Hosseinibarkooie et al. 2016). The localization of SMN to growth cones in differentiating 
neurons (Fan and Simard 2002; Sharma et al. 2005) along with defects in axonal growth 
of motor neurons in mouse and zebrafish models of SMA (McWhorter et al. 2003; 
Rossoll et al. 2003) indicate a possible function for SMN in neurite outgrowth and axonal 
pathfinding. 
One of the most well-supported snRNP independent roles for SMN is in mRNP 
assembly and transport along motor axons (Rossoll et al. 2003). Evidence for this role 
includes defects in localization of β-actin mRNA in developing motor neurons of SMA 
mice. SMN may regulate levels of other proteins through a connection with phosphatase 
and tensin homolog-mediated (PTEN-mediated) protein synthesis pathways (Ning et al. 
2010) and other modes of translational regulation (Sanchez et al. 2013). SMN has also 
been implicated in neuromuscular junction (NMJ) formation and function (Fan et al. 
2002; Chan et al. 2003; Kariya et al. 2008; Kong et al. 2009; Voigt et al. 2010). 
It is challenging to distinguish between primary and secondary effects in neurons 
and muscles in SMA models since cell autonomy is difficult to establish when the 
functions of motor neurons and muscles are highly interconnected. Nonetheless, SMN 
has been suggested to play a role in some muscle-specific functions. Mouse cells 
differentiating into muscle fibers were used to show that reduced levels of SMN resulted 
in myoblast fusion defects and morphologically abnormal myotubes (Shafey et al. 2005). 
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The severity of these defects was proportional to the level of SMN expression. Rajendra 
et al. (2007) observed localization of SMN to sarcomeres, the contractile units of muscle 
fibers, in Drosophila and in mice. The final piece of evidence for a muscle specific 
function of SMN is that flight muscles in an adult Drosophila model of SMA were 
severely disorganized, suggesting a role for SMN in maintenance of muscle architecture 
(Walker et al. 2008; Bowerman et al. 2009). 
The central question facing researchers in the SMA field is how the loss of a 
protein with an essential and ubiquitous function can cause a primarily neuromuscular 
disease. Current hypotheses suggest that certain tissues, such as neurons or muscles, may 
have a greater requirement for snRNPs thus making them more sensitive to low levels of 
SMN and more susceptible to defects in snRNP biogenesis. It is also possible that 
disruptions to the tissue-specific functions of SMN lead to SMA. These hypotheses need 
not be mutually exclusive.  
Modeling SMA 
Drosophila SMA models 
Integral aspects of cell and developmental biology in humans are conserved in 
Drosophila.  For example, approximately 75% of disease-causing loci in humans have 
homologs in the fly (Reiter et al. 2001).  This conservation means that by modeling 
human disease causing mutations in the fly, we are able to study human disorders in a 
system that is likely to respond with similar pathology as that observed in humans. The 
fruitfly is an especially attractive model organism for numerous reasons including the 
availability of a sequenced genome, the ease of implementing several different genetic 
tools, and a short generation time. Additionally, neuromuscular development in adult flies 
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resembles that of vertebrates in many ways, thus making Drosophila well-suited for 
study of disorders such as SMA (Fernandes et al. 1999). 
The Drosophila Smn ortholog is an intron-less gene that codes for a 226 amino 
acid protein.  Due to the absence of introns, the mechanism of splicing of SMN2 that 
occurs in humans is not optimally studied in this model system. The human and fly 
homologs share 23.5% identity and 36.7% similarity; therefore, several other elements of 
SMN biology can be effectively modeled.  The regions of the protein showing greatest 
conservation correspond to the Gemin2 binding site near the N-terminus, the Tudor 
domain, and the YG box self-oligomerization domain at the C-terminus (Fig. 1.6) 
(Miguel-Aliaga et al. 2000). The Drosophila SMN complex participates in the assembly 
of Sm proteins onto snRNAs, indicating that the function of human SMN in snRNP 
biogenesis is conserved in the fly (Rajendra et al. 2007). 
 
Figure 1.6. SMA patient mutations in the Drosophila Smn gene. Many point mutations in 
SMN1 that cause SMA are at amino acid residues that are conserved in Drosophila. 
These point mutations span all three known functional domains of SMN, the Gemin2 
binding domain, the tudor domain, and the YG Box self-oligomerization domain. This 
point mutations lead to mild, intermediate, and severe defects in the fly, thus representing 
the varying severity of the disease observed in humans. Figure modified from the thesis 
of Kavita Praveen (Praveen, 2012). 
 
Chan et al. (2003) isolated two point mutations in the YG box self-
oligomerization domain of SMN through a small-scale ethyl methane sulphonate (EMS) 
mutagenesis screen.  Mutant animals died during late larval stages and showed loss of 
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mobility and coordination. Several additional Smn mutants have also been generated via 
transposon-mediated mutagenesis (Rajendra et al. 2007; Shpargel et al. 2009). These 
animals vary in the severity of their phenotype based on the location of the insertion. 
Using one of these lines that contained a transposon insertion upstream of Smn, an Smn 
null allele was used in an imprecise excision screen to generate a deletion that removes 
the promoter, open reading frame, and part of the 3` UTR of SMN (Chang et al. 2008). 
This fly model of SMA, called SmnX7, is useful for the study of larval phenotypes but not 
adult phenotypes since animals die as larvae without pupating.  In addition, these models 
do not recapitulate human SMA, which is caused by a reduction, but not complete loss, of 
functional protein.   
The number of Drosophila melanogaster SMA models expanded when a series of 
flies were developed where the endogenous Smn gene is replaced with a Flag-Smn 
transgene expressing either wild-type SMN or SMN containing patient-derived point 
mutations at conserved amino acids (Fig. 1.6) (Praveen et al. 2012; Praveen et al. 2014). 
Although it is highly similar to human SMN1 and SMN2, the entire open reading frame of 
fruitfly Smn is contained within a single exon, and so only full-length SMN protein is 
expressed in Drosophila (Rajendra et al. 2007). Without complications introduced by 
splicing, the fruitfly is an excellent model for investigating the functions of the protein in 
isolation. When modeled in the fly, SMA-causing point mutations recapitulate the range 
of phenotypic severity seen in humans (Praveen et al. 2014; Garcia et al. 2016). 
Other animal models of SMA 
SMA has been modeled in numerous additional organisms including mice, fish, 
worms and fission yeast (Miguel-Aliaga et al. 1999; Hsieh-Li et al. 2000; Monani et al. 
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2000; Owen et al. 2000; McWhorter et al. 2003). Severe reduction or complete knockout 
of Smn in all of these organisms is lethal. Moderate reductions in SMN levels in C. 
elegans resulted in an uncoordinated phenotype and lack of muscle tone. This ultimately 
resulted in paralysis in this model system. Moderate loss of SMN in zebrafish led to 
defects in motor axon pathfinding. This occurred without defects in muscles or overt 
movement problems. 
To achieve a milder reduction in SMN levels and obtain a mouse model that more 
closely resembled the human disorder, two groups generated mice that expressed the 
human SMN2 gene in the background of a homozygous mouse Smn mutation (Smn-/-; 
SMN2) (Hsieh-Li et al. 2000; Monani et al. 2000). The inclusion of the human SMN2 
gene in the mouse genome meant that the splicing pattern of the gene in humans was also 
a factor in this model. This rescued the embryonic lethality of Smn-/- mice and they 
presented with many of the pathological features observed in SMA patients. These 
include a shorter lifespan, motor neuron degeneration, and developing muscle weakness 
over time (Monani et al. 2000).  As observed in the human disease, varying the number 
of copies of SMN2 varied the severity of the phenotype from that resembling type I (1 or 
2 copies) patients to complete rescue (8-10 copies). In this way, the full spectrum of the 
human disease can be represented in this model. 
As SMA research progressed, additional mouse models were generated to use in 
studying different aspects of the disease. The ‘Delta7’ mouse (Smn−/−;SMN2;SMNΔ7), is 
a model of severe SMA (Le et al. 2005), and affected mice usually die between postnatal 
day 10 (P10) and P18. This model differs from the previous mouse model of the disease 
because it includes a version of SMN in the genome that exclusively encodes for the 
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SMNΔ7 transcript, meaning that its splicing cannot be modulated, in addition to having a 
copy of human SMN2. The 2B/– mouse (Smn2B/–) is a model of intermediate SMA 
(Bowerman et al. 2012; Rindt et al. 2015) and these animals survive much longer before 
dying, typically between P25 and P45. This provides a longer window for conducting 
experiments, which can provide insights into disease pathology that cannot be gained 
when animals die very early. 
Oligomeric properties of SMN complexes 
The C-terminal YG box self-oligomerization domain of SMN has been examined 
using X-ray crystallographic studies (Martin et al. 2012; Gupta et al. 2015). Hydrophobic 
interactions, similar to those found in glycine zipper domains of certain transmembrane 
channel proteins, are responsible for dimerization of the protein. (Fig. 1.2). The core of 
this YG box helical domain contains a highly conserved YxxxYxxxY motif. 
More than half of the known SMA patient missense mutations are found within 
the YG box (Burghes et al. 2009; Li et al. 2014; Wirth 2000). Speaking to the importance 
of oligomerization in SMN function, mutations that completely disrupt SMN’s ability to 
self-interact display severe phenotypes in human SMA patients and in animal models 
(Lefebvre et al. 1997; Lorson et al. 1998; Praveen et al. 2014; Clermont et al. 2004; Wirth 
et al. 1999; Pellizzoni et al. 1999; Workman et al. 2009). 
The exact composition and stoichiometry of the various complexes formed by 
SMN are not well understood. In vitro, SMN-Gem2 exists as a stable heterodimer that, 
for purposes of discussing higher order oligomerization, can be considered as a single 
structural unit (Fischer et al. 1997; Sarachan et al. 2012). As the concentration of SMN-
Gem2 increases in solution, this unit exists in an equilibrium mixture containing dimers, 
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tetramers and octamers (Gupta et al. 2015). There are two possibilities for the way in 
which SMN tetramers are formed: by a dimer of dimers or by forming symmetric 
bundles. Further analysis of this question has revealed they are composed of a dimer of 
dimers. 
Only dimers and tetramers are detected in fission yeast, in contrast to human 
SMN-Gem2, which forms dimers to octamers and possibly even larger complexes. 
Octamers appear to form due to self-association of tetramers, although a hexameric SMN 
complex cannot be ruled out. Human SMN-Gem2 co-sediments with Gemins3–8 in vivo 
(Paushkin et al. 2000), however, the relative stoichiometries of these proteins are 
unknown. 
SMN Protein Stability 
The stability of full-length SMN and SMNΔ7 protein has been the subject of 
many studies, given that SMA is caused by low levels of SMN protein. SMNΔ7 protein 
produced from the SMN2 gene is known to be unstable. The SMNΔ7 protein has a 
twofold shorter half-life than full-length SMN in cells (Burnett et al. 2009). SMNΔ7 is 
also not thought to be fully functional compared with full-length SMN protein (Lorson et 
al. 1998; Pellizzoni et al. 1999). Biochemical studies have shown that SMNΔ7 protein 
does not oligomerize well and interactions with established binding partners, such as the 
snRNP Sm proteins, are decreased. Mutations in full-length SMN that inhibit 
oligomerization and prevent complex formation also reduce half-life, suggesting that 
SMN protein stability is modulated by complex formation (Burnett et al. 2009). 
The cause of SMNΔ7 instability was investigated by Cho and Dreyfuss (2010) 
using a luciferase reporter system of protein stability. They identified a degron motif at 
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the C-terminus of SMNΔ7 (268YMSGYHTGYYMEMLA282). It was thought to be created 
in SMN∆7 by SMN2 alternative splicing since it includes the EMLA amino acids that are 
specific to SMNΔ7. Identified through scanning alanine mutagenesis of the C-terminus, 
mutation of serine 270 to alanine was shown to stabilize SMN∆7 constructs in human 
cells. Overexpression of SMN∆7S270A in SMN-deficient chicken DT40 cells rescued their 
viability, indicating some functionality of stabilized SMN∆7 protein. Factors responsible 
for specifically mediating SMN∆7 degradation have not been identified.  
Intracellular proteins can be degraded or cleaved by a variety of different 
proteolytic systems including the calcium-activated neutral protease (calpain) system, 
lysosomal proteases, autophagy, and the ubiquitin proteasome system (UPS). SMN has 
been shown to be a proteolytic target of Calpain (Walker et al. 2008; Fuentes et al. 2010). 
Inhibition of the lysosome, autophagy, and the proteasome revealed that only proteasome 
inhibition significantly increased SMN protein levels. This and other experiments show 
ubiquitylation pathways regulate the stability and degradation of SMN (Chang et al. 
2004; Burnett et al. 2009; Hsu et al. 2010). 
Ubiquitin Proteasome System (UPS) and SMN 
In the UPS, proteins are tagged by linkage to ubiquitin through the action of three 
factors (Fig. 1.7) (Petroski 2008). E1 proteins activate ubiquitin and transfer it to the E2 
enzyme. E2 proteins conjugate ubiquitin to their substrates. E3 proteins recognize the 
substrate and assist in the transfer of ubiquitin from the E2. Since E3 ligases confer 
substrate specificity, they are often considered as candidates for targeted inhibition of 
protein degradation. 
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Figure 1.7. The ubiquitin proteasome system (UPS) involves three types of proteins: E1 
ubiquitin activating enzymes, E2 ubiquitin conjugating enzymes, and E3 ubiquitin ligase 
enzymes. E3 ubiquitin ligases recognize target substrates and ubiquitylate them, leading 
to their degradation by the proteasome. In other cases, ubiquitylation occurs without 
leading directly to proteasome targeting and degradation. Figure adapted from Elledge 
lab, Harvard. 
 
Ubiquitin homeostasis is thought to be especially important for neuromuscular 
pathology in SMA (Groen and Gillingwater 2015). X-linked infantile SMA is caused by 
mutations in ubiquitin-like modifier activating enzyme 1 (UBA1) (Ramser et al. 2008; 
Schmutzler et al. 2008). Furthermore, mouse models of SMA have disrupted levels of the 
E1 protein, UBA1 (Wishart et al. 2014). Finally, ubiquitylation pathways have been 
shown to specifically affect axonal and synaptic stability (Korhonen and Lindholm 2004). 
SMN protein degradation via the UPS has been well-established (Chang et al. 
2004; Burnett et al. 2009; Kwon et al. 2011). Since the E3 ligases are the most specific 
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part of the UPS for their ubiquitylation targets, investigators have studied E3 ligases of 
SMN using candidate approaches (Han et al. 2016; Hsu et al. 2010; Kwon et al. 2013). 
As outlined below, researchers have discovered E3 ligases that target SMN for 
degradation in cultured human cells through these studies. It is therefore likely that SMN 
is targeted by multiple E3 ubiquitin ligases, as this mechanism of regulation has been 
demonstrated for a number of proteins (e.g. p53; Jain and Barton 2010). Ubiquitylation 
does not always result in immediate destruction of the target (Mukhopadhyay and 
Riezman 2007; Ikeda and Dikic 2008; Liu and Walters 2010). Different functions arise 
based on the type of lysine linkage between ubiquitin molecules and the length of the 
ubiquitin chain that is created. 
Mindbomb1 (Mib1) 
Kwon et al. (2013) identified the E3 ubiquitin ligase, mind bomb 1 (Mib1), as 
interacting with and ubiquitylating SMN, leading to subsequent degradation. It was 
originally chosen as a candidate E3 ubiquitin ligase due to its role in inhibition of the 
outgrowth of neurites in cultured neurons (Choe et al. 2007). Additionally, loss of Mib1 
in Drosophila melanogaster had been shown to increase the number of synaptic boutons 
at neuromuscular junctions, producing synaptic overgrowth. Evidence for Mib1 targeting 
SMN for degradation included the experiment that revealed Mib1 knockdown in cultured 
cells increases SMN protein levels. Additionally, in SMN deficient C. elegans, 
neuromuscular function improved following knockdown of the Mib1 ortholog as 
measured in a pharyngeal pumping assay, indicating a physiological role for Mib1 in 
modulating SMN. Kwon et al. (2013) also mapped the interacting domains of Mib1 and 
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SMN, demonstrating the interaction is mediated by the N-terminal domain of Mib1 and 
the part of SMN protein encoded for by exon 6. 
Itch 
In some cases, protein ubiquitylation does not result in destruction of the target. 
Different types of ubiquitin lysine linkages or different chain lengths can affect other 
aspects of protein function within the cell, including cellular localization. SMN is found 
in both the cytoplasm and nucleus. In the nucleus, SMN is concentrated in nuclear bodies 
– Cajal bodies, gems, and the nucleolus of neurons (Stanek and Neugebauer, 2006; Liu 
and Dreyfuss 1996). Posttranslational modifications are thought to affect this cellular 
localization. Han et al. (2016) reported that the E3 ubiquitin ligase called Itch directly 
interacts with and monoubiquitylates SMN. This had a modest effect on protein 
degradation and a more pronounced effect on cellular localization of SMN. This 
mislocalization of SMN was shown to impair Cajal body integrity and findings suggested 
impairment of snRNP maturation. 
SCFSlmb/SCFB-TrCP 
SCF complexes are one type of E3 ligase that operates as part of the UPS. SCF 
complexes are different from many other E3 ubiquitin ligases because multiple proteins 
function together to ubiquitylate substrates, in contrast to other E3 ligases that are single 
proteins (Willems et al. 2004). SCFSlmb/SCFB-TrCP consists of Cullin1 (Cul1), Slmb/B-
TrCP, and SkpA. Cul1 forms the major structural scaffold of this horseshoe-shaped, 
multi-subunit complex (Zheng et al. 2002). Slmb/B-TrCP is an F-box protein and is the 
substrate recognition component (Jiang and Struhl 1998). SkpA is a bridging protein 
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essential for interaction of Cul1 with the F-box protein (Patton et al. 1998a; Patton et al. 
1998b). 
The SCFSlmb/SCFB-TrCP complex is one of the best-characterized SCF E3 ligases in 
animals (Willems et al. 2004). SCFSlmb is the Drosophila melanogaster homolog of SCFB-
TrCP in mammals (Bocca et al. 2001). Initial analysis of this SCF pathway revealed that 
SCFSlmb/SCFB-TrCP catalyzes the phosphorylation-dependent ubiquitylation of the NFKB 
inhibitor IKB and the transcription factor B-catenin (Yaron et al. 1998; Winston et al. 
1999). Most known substrates contain the amino acid sequence DGSXXS degron motif 
or a variant thereof. Both serine, or in some cases threonine, residues need to be 
phosphorylated for efficient recognition of the degron in the substrate by the E3 ligase. 
Since the discovery and characterization of these two substrates of SCFSlmb/SCFB-TrCP 
numerous additional substrates have been identified using substrate trapping proteomics 
analysis and other approaches (Kim et al. 2015; Skwarek et al. 2014). The work 
described here describes the identification of a novel SCFSlmb/SCFB-TrCP substrate, SMN 
protein. 
 
Research Objectives 
Spinal muscular atrophy is a neuromuscular disorder caused by loss of, or 
mutation in, the SMN1 gene. The best-characterized function of SMN is in the biogenesis 
of snRNPs, core components of the spliceosome. The mechanism of SMA disease 
pathology has remained unclear despite over 20 years of research. One of the most 
pressing questions in the field relates to the fact that SMA is primarily a neuromuscular 
disorder, but SMN is known to have an ubiquitous and essential function. Our approach 
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to elucidate critical functions of SMN in SMA is to examine SMN protein interaction 
partners in a whole organism during early stages of development. To do this, we used 
previously created transgenic flies expressing only Flag-SMN to characterize SMN 
complexes using Flag immunoprecipitation followed by mass spectrometry. These 
interactions have provided insight into the mechanisms of degradation of SMN. 
Additionally, identification of novel binding partners provides the foundation for 
exploration of molecular mechanisms related to alternative functions of SMN. 
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CHAPTER II: Self-oligomeriation regulates stability of Survival Motor 
Neuron (SMN) protein isoforms by sequestering an SCFSlmb degron1 
 
Introduction 
Spinal muscular atrophy (SMA) is a common neuromuscular disorder, recognized 
as the most prevalent genetic cause of early childhood mortality (Pearn 1980). Patients 
with the most severe form of the disease, which is also the most common, become 
symptomatic in the first six months of life and rarely live past two years (Wee et al. 2010; 
Prior 2010). Because the onset of symptoms and their severity can vary, SMA has 
historically been classified into three subtypes (Ogino and Wilson 2004). More recently, 
clinicians have recognized that SMA is better characterized as a continuous spectrum 
disorder, ranging from acute (prenatal onset) to nearly asymptomatic (Tiziano et al. 
2013). Clinically, SMA patients experience degeneration of motor neurons in the anterior 
horn of the lower spinal cord (Crawford and Pardo 1996). This leads to progressive 
atrophy of proximal muscle groups, ultimately resulting in loss of motor function and 
symmetrical paralysis. The cause of death is often restrictive respiratory failure (Kolb and 
Kissell 2015). 
SMA typically results from homozygous deletion of the survival motor neuron 1 
(SMN1) gene (Lefebvre et al. 1995). A small fraction of SMA patients have lost one copy 
of SMN1 and the remaining copy contains a point mutation (Burghes and Beattie 2009). 
                                                
1 This chapter previously appeared as an article in Molecular Biology of the Cell. The original citation is as 
follows: Gray, K. M., Kaifer, K. A., Baillat, D., et al. (2018). Self-oligomerization regulates stability of 
survival motor neuron protein isoforms by sequestering an SCFSlmb degron. Molecular Biology of the Cell, 
29(2), 96-110. 
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Humans have two SMN paralogs, named SMN1 and SMN2, both of which contribute to 
total cellular levels of SMN protein. SMN2 exon 7 contains a silent base change that 
alters splicing to primarily produce a truncated, unstable protein product called SMN∆7 
(Lorson et al. 1999; Monani et al. 1999; Lorson and Androphy 2000). The last 16 amino 
acids of SMN are replaced in SMNΔ7 by four amino acids, EMLA, encoded by exon 8. 
Current estimates suggest that SMN2 produces 10-15% of the level of full-length protein 
produced by SMN1 (Lorson et al. 2010). Complete loss of SMN is lethal in all organisms 
investigated to date (O’Hearn et al. 2016). Although the amount of full-length protein 
produced by SMN2 is not enough to compensate for loss of SMN1, SMN2 is sufficient to 
rescue embryonic lethality (Monani et al. 2000). SMA is therefore a disease that arises 
due to a hypomorphic reduction in SMN levels (Lefebvre et al. 1995). Furthermore, 
relative levels of the SMN protein correlate with the phenotypic severity of SMA 
(Coovert et al. 1997; Lefebvre et al. 1997). 
Whereas a causative link between SMN1 and SMA was established over 20 years 
ago, the molecular role of SMN in disease etiology remains unclear. SMN is the central 
component of a multimeric protein assemblage known as the SMN complex (Matera and 
Wang 2014; Li et al. 2014). The best-characterized function of this complex, which is 
found in all tissues of metazoan organisms, is in the cytoplasmic assembly of small 
nuclear ribonucleoproteins (snRNPs), core components of the spliceosome (Fischer et al. 
1997; Meister et al. 2001; Pellizzoni et al. 2002). 
Although it is ubiquitously expressed, SMN has also been implicated in a number 
of tissue-specific processes related to neurons and muscles. These functions include actin 
dynamics (Oprea et al. 2008; Ackermann et al. 2013), axonal pathfinding (Fan and 
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Simard 2002; McWhorter et al. 2003; Sharma et al. 2005), axonal transport of β-actin 
mRNP (Rossoll et al. 2003), phosphatase and tensin homolog-mediated (PTEN-
mediated) protein synthesis pathways (Ning et al. 2010), translational regulation 
(Sanchez et al. 2013), neuromuscular junction formation and function (Chan et al. 2003; 
Kariya et al. 2008; Kong et al. 2009; Voigt et al. 2010), myoblast fusion (Shafey et al. 
2005) and maintenance of muscle architecture (Rajendra et al. 2007; Walker et al. 2008; 
Bowerman et al. 2009). 
Ubiquitylation pathways have been shown to regulate the stability and 
degradation of SMN (Chang et al. 2004; Burnett et al. 2009; Hsu et al. 2010) as well as 
axonal and synaptic stability (Korhonen and Lindholm 2004). In the ubiquitin proteasome 
system (UPS), proteins destined for degradation are tagged by linkage to ubiquitin 
through the action of three factors (Petroski 2008). E1 proteins activate ubiquitin and 
transfer it to the E2 enzyme. E2 proteins conjugate ubiquitin to their substrates. E3 
proteins recognize the substrate and assist in the transfer of ubiquitin from the E2. 
Because E3 ligases confer substrate specificity, they are typically considered as 
candidates for targeted inhibition of protein degradation. Ubiquitin homeostasis is 
thought to be particularly important for neuromuscular pathology in SMA (Groen and 
Gillingwater 2015). Indeed, mouse models of SMA display widespread perturbations in 
UBA1 (ubiquitin-like modifier activating enzyme 1) levels (Wishart et al. 2014). 
Furthermore, mutations in UBA1 are known to cause X-linked infantile SMA (Ramser et 
al. 2008; Schmutzler et al. 2008). 
Given the importance of these processes to normal development as well as 
neurodegenerative disease, we set out to identify and characterize novel SMN binding 
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partners. Previously, we developed Drosophila melanogaster as a model system wherein 
the endogenous Smn gene is replaced with a Flag-Smn transgene (Praveen et al. 2012). 
Although it is highly similar to human SMN1 and SMN2, the entire open reading frame of 
fruitfly Smn is contained within a single exon, and so only full-length SMN protein is 
expressed in Drosophila (Rajendra et al. 2007). When modeled in the fly, SMA-causing 
point mutations recapitulate the full range of phenotypic severity seen in humans 
(Praveen et al. 2014; Garcia et al. 2016). Using this system, we carried out proteomic 
profiling of Flag-purified embryonic lysates and identified the SCFSlmb E3 ubiquitin 
ligase complex as a novel SMN interactor. Importantly, this interaction is conserved from 
flies to humans. We show that SCFSlmb binding requires a phospho-degron motif located 
within the SMN self-oligomerization domain, mutation of which stabilizes SMN∆7 and, 
to a lesser extent, full-length SMN. Additional studies in flies, mice and human cells 
elucidate a disease-relevant mechanism whereby SMN protein stability is regulated by 
self-oligomerization. Other E3 ligases have been reported to target SMN for degradation 
in cultured human cells (Han et al. 2016; Hsu et al. 2010; Kwon et al. 2013). Given our 
findings in fruit fly embryos, SMN is likely targeted by multiple E3 ubiquitin ligases. 
Experimental procedures 
Fly stocks and transgenes 
Oregon-R was used as the wild-type control. The SmnX7 microdeletion allele 
(Chang et al. 2008) was a gift from S. Artavanis-Tsakonis (Harvard University, 
Cambridge, USA). This deficiency removes the promoter and the entire SMN coding 
region, leaving only the final 44bp of the 3’ UTR. All stocks were cultured on molasses 
and agar at room temperature (24 ± 1°C) in half-pint bottles. The Smn transgenic 
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constructs were injected into embryos by BestGene Inc. (Chino Hills, CA) as described in 
Praveen et al. 2014. In short, a ~3kb fragment containing the entire Smn coding region 
was cloned from the Drosophila genome into the pAttB vector (Bischof et al. 2007). A 
3X FLAG tag was inserted immediately downstream of the start codon of dSMN. Point 
mutations were introduced into this construct using Q5 (NEB) site-directed mutagenesis 
according to manufacturer’s instructions. The basal Smn construct used, vSmn, contained 
three single amino acid changes and the addition of the MGLR motif to make fruitfly 
Smn more similar to the evolutionarily conserved vertebrate Smn. Subsequently 
generated constructs used vSmn as a template and consist of the amino acid changes 
detailed in Figure 4. Y203C, G206S, and G210V were previously published in Praveen et 
al. 2014. 
Drosophila embryo protein lysate and mass spectrometry 
0-12h Drosophila embryos were collected from Oregon-R control and Flag-SMN 
flies, dechorionated, flash frozen, and stored at -80C. Embryos (approx. 1gr) were then 
homogenized on ice with a Potter tissue grinder in 5 mL of lysis buffer containing 
100mM potassium acetate, 30mM HEPES-KOH at pH 7.4, 2mM magnesium acetate, 
5mM dithiothreitol (DTT) and protease inhibitor cocktail. Lysates were centrifuged twice 
at 20000 rpm for 20min at 4C and dialyzed for 5h at 4C in Buffer D (HEPES 20mM pH 
7.9, 100mM KCl, 2.5 mM MgCl2, 20% glycerol, 0.5 mM DTT, PMSF 0.2 mM). Lysates 
were clarified again by centrifugation at 20000 rpm for 20 min at 4C. Lysates were flash 
frozen using liquid nitrogen and stored at -80C before use. Lysates were then thawed on 
ice, centrifuged at 20000 rpm for 20 min at 4C and incubated with rotation with 100 mL 
of EZview Red Anti-FLAG M2 affinity gel (Sigma) for 2h at 4C. Beads were washed a 
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total of six times using buffer with KCl concentrations ranging from 100mM to 250mM 
with rotation for 1 min at 4C in between each wash. Finally, Flag proteins were eluted 3 
consecutive times with one bed volume of elution buffer (Tris 20mM pH 8, 100 mM 
KCl, 10% glycerol, 0.5 mM DTT, PMSF 0.2 mM) containing 250ug/mL 3XFLAG 
peptide (sigma). The entire eluate was used for mass spectrometry analysis on an 
Orbitrap Velos instrument, fitted with a Thermo Easy-spray 50cm column. 
Tissue culture and transfections 
S2 cell lines were obtained from the Drosophila Genome Resource Center 
(Bloomington, IL). S2 cells were maintained in SF900 SFM (Gibco) supplemented with 
1% penicillin/streptomycin and filter sterilized. Cells were removed from the flask using 
a cell scraper and passaged to maintain a density of approximately 106-107 cells/mL. S2 
cells were transferred to filter sterilized SF900 SFM (Gibco) without antibiotics prior to 
transfection with Cellfectin II (Invitrogen). Transfections were performed according to 
Cellfectin II protocol in a final volume of 4 mL in a T-25 flask containing 107 cells that 
were plated one hour before transfection. The total amount of DNA used in transfections 
was 2.5ug. Human embryonic kidney HEK-293T and HeLa cells were maintained at 37C 
with 5% CO2 in DMEM (Gibco) supplemented with 10% FBS and 1% 
penicillin/streptomycin (Gibco). 1x106 - 2x106 cells were plated in T-25 flasks and 
transiently transfected with 1-2ug of plasmid DNA per flask using Lipofectamine 
(Invitrogen) or FuGENE HD transfection reagent (Roche Applied Science, Indianapolis, 
IN) according to the manufacturer’s protocol. Cells were harvested 24-72 h 
posttransfection.  
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For siRNA transections, HeLa cells were plated subconfluently in T-25 flasks and 
transfected with 10nm of siRNA (Gift from Mike Emanuele lab) and 17uL Lipofectamine 
RNAi MAX (Invitrogen) in 5mL total media according to manufacturers instructions. 
After 48h of transfection cells were harvested. For RNAi in S2 cells using dsRNA, 107 
cells were plated in each well of a 6-well plate in 1 mL of media. Cells were treated ~ 
every 24h with 10ug/mL dsRNA targeted against Slmb, Oskar, or Gaussia Luciferaese 
(as controls) as described in Rogers and Rogers 2008. 
In vitro binding assay 
GST and GST-SMN were purified from E. coli. In brief, cells transformed with 
BL21*GST-SMN were grown at 37˚C overnight and then induced using 1 mM IPTG. 
Recombinant protein was extracted and purified using Glutathione sepharose 4B beads. 
GST-B-TrCP1 was purchased from Novus Biologicals (cat# H00008945). SMNGem2 
complexes were co-expressed in E. coli using SMN∆5 and Gemin2(12-280) constructs, 
as described in Gupta et al. (2015). Glutathione sepharose 4B beads were washed 3x with 
PBS. GST alone, GST-SMN, or GST-B-TrCP1 were attached to beads during 4h-
overnight incubation at 4˚C in PBS with rotation. Beads were then washed 3x with 
modified RIPA buffer (50mM Tris-HCl, pH 7.5, 250 mM NaCl, 1mM EDTA, 1% NP-
40). 20uL of beads with ~2ug attached GST-tagged protein (as determined by Coomassie 
stain with BSA standard) were added to 200uL modified RIPA buffer with 100ug/mL 
BSA block. 2ug of SMNGem2 was added and the mixture was rotated end over end at 
4˚C overnight. Beads were then washed 3x with modified RIPA buffer and 10uL SDS 
loading buffer was added followed by boiling for 5 minutes. 
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In vivo ubiquitylation assay 
The in vivo ubiquitylation assay was performed as described previously 
(Choudhury et al. 2016). Briefly, HEK-293T cells were transfected as indicated in 10 cm 
dishes using Lipofectamine2000 (Thermo Fisher Scientific). The day after, cells were 
treated with 20 µM of MG132 for 4 hours and then harvested in PBS. 80% of the cell 
suspension was lysed in 6M Guanidine-HCl containing buffer and used to pull down His-
Ubiquitinated proteins on Ni2+-NTA beads, while the remaining 20% was used to 
prepare inputs. Ni2+ pull down eluates and inputs were separated through SDS-PAGE 
and analyzed by western blot. 
Cycloheximide treatment 
Following RNAi treatment, S2 cells were pooled, centrifuged and resuspended in 
fresh media. 1/3 of these cells were frozen and taken as the 0h timepoint.  The remainders 
of the cells were replated in 6 well plates. 100ug/mL cycloheximide (CHX) was added to 
each sample, and cells were harvested at 2 and 6 hours following treatment. 
Immunoprecipitation 
Clarified cell lysates were precleared with immune-globulin G (IgG) agarose 
beads for 1h at 4C and again precleared overnight at 4C. The precleared lysates were then 
incubated with Anti-FLAG antibody crosslinked to agarose beads (EZview Red Anti-
FLAG M2 affinity gel, Sigma) for 2h at 4C with rotation. The beads were washed with 
lysis buffer or modified lysis buffer six times and boiled in SDS gel-loading buffer. 
Eluted proteins were run on an SDS-PAGE for western blotting. 
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Antibodies and Western blotting 
Larval and adult lysates were prepared by crushing the animals in lysis buffer 
(50mM Tris-HCl, pH 7.5, 150 mM NaCl, 1mM EDTA, 1% NP-40) with 1X (adults) or 
10x (larvae) protease inhibitor cocktail (Invitrogen) and clearing the lysate by 
centrifugation at 13,000 RPM for 10 min at 4ºC. S2 cell lysates were prepared by 
suspending cells in lysis buffer (50mM Tris-HCl, pH 7.5, 150 mM NaCl, 1mM EDTA, 
1% NP-40) with 10% glycerol and 1x protease inhibitor cocktail (Invitrogen) and 
disrupting cell membranes by pulling the suspension through a 25 gauge needle (Becton 
Dickinson). The lysate was then cleared by centrifugation at 13,000 RPM for 10 min at 
4ºC. Human cells (293Ts and HeLas) were first gently washed in ice-cold 1X PBS, then 
collected in ice-cold 1X PBS by scraping. Cells were pelleted by spinning at 1000 rpm 
for 5 min. The supernatant was removed and cells were resuspended in ice cold lysis 
buffer (50mM Tris-HCl, pH 7.5, 150 mM NaCl, 1mM EDTA, 1% NP-40) and allowed to 
lyse on ice for 30 min. After lysing, the lysate was cleared by centrifuging the cells for 10 
min at 13000 at 4C. Western blotting on lysates was performed using standard protocols. 
Rabbit anti-dSMN serum was generated by injecting rabbits with purified full-length 
dSMN protein (Pacific Immunology Corp, CA), and was subsequently affinity purified. 
For Western blotting, dilutions of 1 in 2,500 for the affinity purified anti-dSMN, 1 in 
20,000 (fly) or 1 in 5,000 (human) for anti-α tubulin (Sigma), 1 in 10,000 for monoclonal 
anti-Flag (Sigma), 1 in 1,000 for anti-Slmb (gift from Greg Rogers), 1 in 2,500 for anti-
human SMN (BD Biosciences), 1 in 1,000 for anti-B-TrCP (gift from MB Major lab), 1 
in 10,000 for polyclonal anti-Myc (Santa Cruz), and 1 in 2,000 for anti-GST (abcam) 
were used. 
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Larval locomotion 
Smn control and mutant larvae (73-77 hours post egg-laying) were placed on a 
1.5% agarose molasses tray five at a time. The tray was then placed in a box with a 
camera and the larvae were recorded moving freely for 60 seconds. Each set of larvae 
was recorded three times, and one video was chosen for analysis based on video 
quality. The videos were then converted to AVI files and analyzed using the wrMTrck 
plug-in of the Fiji software. The "Body Lengths per Second" was calculated in wrMTrck 
by dividing the track length by half the perimeter and time (seconds). P-values were 
generated using a multiple comparison ANOVA.  
SMA Mouse Models 
Two previously developed SMA mouse models were utilized. The ‘Delta7’ 
mouse (Smn−/−;SMN2;SMNΔ7), is a model of severe SMA (Le et al. 2005). The ‘2B/–‘ 
mouse (Smn2B/–) is a model of intermediate SMA (Bowerman et al. 2012; Rindt et al. 
2015). Adeno-associated virus serotype 9 (AAV9) delivered SMN cDNA isoforms to 
these SMA mice, as previously described (Foust et al. 2010; Passini et al. 2010; Valori et 
al. 2010; Dominguez et al. 2011; Glascock et al. 2012). Gross motor function was 
measured using a modified tube-test which tests the ability of mice to splay their legs and 
maintain a hanging position. 
Human iPSC Cell culture 
Human iPSCs from two independent unaffected control and two SMA patient 
lines were grown as pluripotent colonies on Matrigel substrate (Corning) in Nutristem 
medium (Stemgent). Colonies were then lifted using 1mg/ml Dispase (Gibco) and 
maintained as floating spheres of neural progenitor cells in the neural progenitor growth 
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medium Stemline (Sigma) supplemented with 100ng/ml human basic fibroblast growth 
factor (FGF-2, Miltenyi), 100ng/ml epidermal growth factor (EGF, Miltenyi), and 5µg/ml 
heparin (Sigma-Aldrich) in ultra-low attachment flasks. Aggregates were passaged using 
a manual chopping technique as previously described (Svendsen et al. 1998; Ebert et al. 
2013). To induce motor neuron differentiation, neural progenitor cells were cultured in 
neural induction medium (1:1 DMEM/F12 (Gibco), 1x N2 Supplement (Gibco), 5µg/mL 
Heparin (Sigma), 1x Non-Essential Amino Acids (Gibco), and 1x Antibiotic-Antimycotic 
(Gibco)) plus 0.1µM all-trans retinoic acid (RA) for two weeks; 1µM Purmorphamine 
(PMN, Stemgent) was added during the second week. Spheres were then dissociated with 
TrypLE Express (Gibco) and plated onto Matrigel-coated 12mm coverslips in NIM plus 
1µM RA, 1µM PMN, 1x B27 Supplement (Gibco), 200ng/mL Ascorbic Acid (Sigma), 
1µM cAMP (Sigma), 10ng/mL BDNF (Peprotech), 10ng/mL GDNF (Peprotech)). One 
week post-plating, cells were infected with lentiviral vectors (MOI = 5) expressing 
mCherry alone or SMN S270A-IRES-mCherry. Transgenes in both viruses were under 
the control of the EF1α promoter. Uninfected cells served as controls. Cells were 
analyzed at 1 and 3 weeks post-infections, which was 4 and 6 weeks of total 
differentiation (Ebert et al. 2009; Sareen et al. 2013). 
Immunocytochemistry 
Coverslips were fixed in 4% paraformaldehyde (Electron Microscopy Sciences) 
for 20 minutes at room temperature and rinsed with PBS. Cells were blocked with 5% 
Normal Donkey Serum (Millipore) and permeabilized in 0.2% TritonX-100 (Sigma) for 
30 minutes at room temperature. Cells were then incubated in primary antibody solution 
for 1 hour, rinsed with PBS, and incubated in secondary antibody solution for 1 hour at 
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room temperature. Finally, nuclei were labeled with Hoechst nuclear stain (Sigma) to 
label DNA and mounted onto glass slides using FluoroMount medium 
(SouthernBiotech). Primary antibodies used were mouse anti-SMI-32 (Covance SMI-
32R, 1:1000) and rabbit anti-mCherry (ThermoFisher, 1:1000). Secondary antibodies 
used were donkey anti-rabbit Cy3 (Jackson Immunoresearch 711-165-152) and donkey 
anti-mouse AF488 (Invitrogen A21202). 
Immunocytochemical Analysis 
Images were acquired from five random fields per coverslip using an inverted 
fluorescent microscope (Nikon) and NIS Elements software. Images were blinded and 
manually analyzed for antigen specificity with NIS Elements software.  
Results 
Flag-SMN interacts with UPS (ubiquitin proteasome system) proteins 
We previously generated transgenic flies that express Flag-tagged SMN proteins 
in an otherwise null Smn background (Praveen et al. 2012). To preserve endogenous 
expression patterns, the constructs are driven by the native promoter and flanking 
sequences. As described in the Methods, we intercrossed hemizygous Flag-
SmnWT,SmnX7/SmnD animals to establish a stock wherein all of the SMN protein, 
including the maternal contribution, is epitope-tagged. After breeding them for >100 
generations, essentially all of the animals are homozygous for the Flag-SmnWT transgene, 
but second site recessive mutations are minimized due to the use of two different Smn 
null alleles. Adults from this stock display no apparent defects and have an eclosion 
frequency (~90%) similar to that of wild-type (Oregon-R) animals.   
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We collected (0-12h) embryos from Flag-SmnWT/WT,SmnX7/D (SMN) and Oregon-
R (Ctrl) animals and analyzed Flag-purified lysates by ‘label-free’ mass spectrometry. In 
addition to Flag-SMN, we identified SMN complex components Gemin2 and Gemin3, 
along with all seven of the canonical Sm-core snRNP proteins (Fig. 1A). We also 
identified the U7-specific Sm-like heterodimer Lsm10/11 (Pillai et al. 2003) and the 
Gemin5 orthologue, Rigor mortis (Gates et al. 2004). Previous studies of Schneider2 (S2) 
cells transfected with epitope-tagged Smn had identified most of the proteins listed above 
as SMN binding partners in Drosophila (Kroiss et al. 2008). However, despite 
bioinformatic and cell biological data indicating that Rigor mortis is part of the fruit fly 
SMN complex, this protein failed to co-purify with SMN in S2 cells (Kroiss et al. 2008; 
Cauchi et al. 2010; Guruharsha et al. 2011). On the basis of our purification data, we 
conclude that the conditions are effective and that Rigor mortis/Gemin5 is an integral 
member of the SMN complex in flies.  
A detailed proteomic analysis of these flies will be presented elsewhere. As 
shown in Fig. 1B, our preliminary analysis identified 396 proteins, 114 of which were 
detected only in the Flag-SMN sample and not in the control. An additional 279 proteins 
were detected in both the Flag purification and control samples. In addition to SMN 
complex members, we co-purified numerous factors that are part of the ubiquitin 
proteasome system (UPS; Fig. 1C). Among these UPS proteins, we identified Cullin 1 
(Cul1), Skp1-related A (SkpA), and supernumerary limbs (Slmb), as being highly 
enriched (>10 fold) in Flag-SMN samples as compared to the control. Together, these 
proteins comprise the SCFSlmb E3 ubiquitin ligase. Cul1 forms the major structural 
scaffold of this horseshoe-shaped, multi-subunit complex (Zheng et al. 2002). Slmb is an 
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F-box protein and is the substrate recognition component (Jiang and Struhl 1998). SkpA 
is a bridging protein essential for interaction of Cul1 with the F-box protein (Patton et al. 
1998a; Patton et al. 1998b). Because of its role in substrate recognition, Slmb is likely to 
be the direct interacting partner of SMN within the SCFSlmb complex. For this reason, we 
focused on Slmb for the initial validation. As shown, Slmb was easily detectable in Flag-
purified eluates from embryos expressing Flag-SMN and nearly undetectable in those 
from control embryos (Fig. 1D). SmB and SmD3 were also easily detectable by western 
blot in Flag-purified embryonic lysates and were used as positive controls for known 
protein interaction partners of SMN. Tubulin and α-Actinin were not detected as 
interacting with SMN in our purification and demonstrate the specificity of the detected 
SMN interactions. 
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Figure 2.1. Flag-SMN immunopurified lysates contain known protein interaction 
partners and ubiquitin proteasome system (UPS) proteins. A. Lysates from Oregon-R 
control (Ctrl) Drosophila embryos and embryos expressing only transgenic Flag-SMN 
(SMN) were Flag-immunopurified and protein eluates were separated by gel 
electrophoresis and silver stained. Band identities predicted by size using information 
from panels C and D. B. Direct mass spectrometric analysis of the eluates (which were 
not gel purified) identified a total of 396 proteins, 114 of which were detected only in 
SMN sample and 279 of which were detected in both SMN and Ctrl samples. C. Flag-
purified eluates were analyzed by ‘label-free’ mass spectrometry. Numerous proteins that 
copurify with Flag-SMN are part of the ubiquitin proteasome system (UPS). Of these 
UPS proteins, Cullin 1 (Cul 1), SkpA, and supernumerary limbs (Slmb), were highly 
enriched (at least 10 fold) in the SMN sample as compared to Ctrl. D. Western blot 
analysis of Flag-purified eluates was used to further validate the presence or absence of 
 45 
SMN interaction partners. Flag-SMN was successfully purified from SMN embryos, but 
was undetectable in the control. As positive controls for known protein interaction 
partners of SMN, SmB and SmD3 were also easily detectable by western blotting using 
anti-Sm antibodies. The presence of Slmb was verified using anti-Slmb. α-Actinin and 
Tubulin were not enriched in our purification and are used as negative controls to 
demonstrate specificity.  
 
SCFSlmb is a bona fide SMN interaction partner that ubiquitylates SMN 
As an E3 ubiquitin ligase, the SCFSlmb complex is a substrate recognition 
component of the ubiquitin proteasome system. As outlined in Fig. 2A, E3 ligases work 
with E1 and E2 proteins to ubiquitylate their targets. The interaction of SCFSlmb with 
SMN was verified in a reciprocal co-immunoprecipitation, demonstrating that Flag-
tagged SCF components form complexes with endogenous SMN (Fig. 2B) in S2 cells. 
SCF complexes are highly conserved from flies to humans: SkpA is 77% identical to 
human Skp1, Cul1 is 63% identical, and Slmb is 80% identical to its human homologs, 
B-TrCP1 and B-TrCP2. Slmb/B-TrCP is the SCF component that directly contacts 
substrates of the E3 ligase. We therefore tested the interaction of recombinant human 
SMN in complex with Gemin2 (SMNGem2) (Gupta et al. 2015) with GST-tagged B-
TrCP1 and -SMN proteins in an in vitro binding assay. As shown in Fig. 2C, 
SMNGem2 did not interact with GST alone, but was detected at high levels following 
pulldown with either GST-SMN (positive control) or GST-B-TrCP1. We also tested the 
interaction of Flag-tagged Drosophila SCF components with endogenous human SMN in 
HEK 293T cells (Fig. 2D). Accordingly, human SMN was co-precipitated with Flag-Cul1 
and Flag-Slmb and at lower levels following Flag-SkpA immunoprecipitation. Flag-B-
TrCP1 and Flag-B-TrCP2, the two human homologs of Slmb, also copurified with 
endogenous human SMN in HEK 293T cells (Fig. 2E). Altogether, these data 
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demonstrate a conserved interaction between SMN and the SCFSlmb/B-TrCP E3 ubiquitin 
ligase complex. 
In order to test the functional consequences of this conserved interaction between 
SMN and SCFSlmb/B-TrCP, a cell based ubiquitylation assay was performed (Fig. 2F). 
Protein lysate from HEK 293T cells transfected with 6xHis-Flag-ubiquitin and GFP-
SMN was purified using a Ni2+ pull down for the tagged ubiquitin. Baseline levels of 
ubiquitylated GFP-SMN were detected using anti-GFP antibody. Following transfection 
of Flag-B-TrCP1 or Flag-B-TrCP2, the levels of ubiquitylated SMN markedly increased 
(Fig. 2F). Ubiquitylation levels were further increased following addition of both proteins 
together. These experiments demonstrate that SCFSlmb/B-TrCP can ubiquitylate SMN in 
vivo.  
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Figure 2.2. Conserved interaction between SMN and the SCFSlmb/B-TrCP E3 ubiquitin 
ligase results in ubiquitylation of SMN. A. E3 ligases work with E1 and E2 proteins to 
ubiquitylate their targets. The SCFSlmb/B-TrCP E3 ubiquitin ligase is made up of three 
proteins: Cul1, SkpA, and Slmb. The E3 ubiquitin ligase is the substrate recognition 
component of the ubiquitin proteasome system. B. Following Cul1-Flag, SkpA-Flag, 
Flag-Slmb and Flag-Gem2 immunoprecipitation from Drosophila S2 cell lysates, western 
analysis using anti-SMN antibody for endogenous SMN was carried out. Co-purification 
of each of the SCF components with endogenous SMN was detected. C. An in vitro 
binding assay tested direct interaction between human SMNΔ5-Gemin2 (SMNGem2) 
(Martin et al. 2012; Gupta et al. 2015) and purified GST-tagged proteins. SMNGem2 
did not interact with GST protein alone, but bound to GST tagged Drosophila SMN 
(GST-SMN) and GST tagged human B-TrCP1 (GST-B-TrCP1). Levels of GST alone, 
GST-SMN, and GST-B-TrCP1 were detected using anti-GST antibody. D. The 
interaction of Flag-tagged Drosophila SCF components with endogenous human SMN 
was tested in in HEK 293T cells. Human SMN was detected at high levels following 
immunoprecipitation of Drosophila Flag-Cul1 and Flag-Slmb and detected at a lower 
level following Drosophila Flag-SkpA immunoprecipitation. E. Flag-tagged versions of 
the human homologs of Slmb, Flag-B-TrCP1 and Flag-B-TrCP2, interact with 
endogenous human SMN in HEK 293T cells demonstrated by Flag-immunopurification 
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followed by immunodetection of SMN. F. Protein lysate from HEK 293T cells 
transfected with 6xHis-Flag-ubiquitin (6HF-Ub) and GFP-SMN was purified using a Ni2+ 
pull down for the tagged ubiquitin. Baseline levels of ubiquitylated GFP-SMN were 
detected using anti-GFP antibody. Following transfection of Flag-B-TrCP1 or Flag-B-
TrCP2, the levels of ubiquitylated SMN markedly increased. Ubiquitylation levels were 
further increased following addition of both proteins together. In the input, GFP-SMN 
was detected using anti-GFP antibody, Flag-B-TrCP1 and Flag-B-TrCP2 were detected 
using anti-Flag antibody, and GAPDH was detected by anti-GAPDH antibody. In the 
Ni2+ pull down, ubiquitylated GFP-SMN was detected using anti-GFP antibody and 6HF-
Ub was detected using anti-Flag antibody to verify successful pull down of tagged 
ubiquitin. 
 
Depletion of Slmb/B-TrCP results in a modest increase in SMN levels 
Given that one of the primary functions of protein ubiquitylation is to target 
proteins to the proteasome, we examined whether depletion of Slmb by RNA interference 
(RNAi) using dsRNA in S2 cells would increase SMN levels (Fig. 3A). Following Slmb 
RNAi, endogenous SMN levels were modestly increased as compared to cells treated 
with control dsRNA. We obtained similar results using an siRNA that targets both B-
TrCP1 and B-TrCP2 in HeLa cells. As shown in Fig. 3B, we detected a modest increase 
in levels of full-length SMN following B-TrCP RNAi, but not control RNAi.  Next, we 
treated S2 cells with cycloheximide (CHX), in the presence or absence of dsRNA 
targeting Slmb, to determine whether differences in SMN levels would be exacerbated 
when production of new proteins was prevented (Fig. 3C). SMN protein levels were also 
specifically targeted using dsRNA against Smn as a positive control for the RNAi 
treatment. At 6 hours post-CHX treatment there was a modest increase in full-length 
SMN levels following Slmb RNAi as compared to the initial timepoint (0h) or the 
negative control (Ctrl) RNAi (Fig. 3C). Together, these data indicate that Slmb/B-TrCP 
participates in the regulation of SMN protein levels. 
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Figure 2.3. Depletion of Slmb/B-TrCP results in an increase of SMN levels. A. Depletion 
of Slmb using 10 day (10d) treatment with dsRNA in Drosophila S2 cells resulted in 
modestly increased SMN levels. Following Slmb RNAi, full-length SMN levels were 
increased as compared to cells treated with control dsRNA against Gaussia Luciferase, 
which is not expressed in S2 cells.  B. The effect of B-TrCP depletion on SMN levels in 
human cells was tested using siRNA that targets both B-TrCP1 and B-TrCP2 in HeLa 
cells. We detected a modest increase in levels of full-length endogenous SMN after B-
TrCP RNAi but not control (scramble) RNAi.  C. Drosophila S2 cells were treated with 
cycloheximide (CHX), an inhibitor of protein synthesis, following Slmb depletion 
following a 3d dsRNA treatment to test whether differences in protein levels would be 
exacerbated when the production of new protein was prevented. SMN protein levels were 
also directly targeted using dsRNA against Smn as a positive control for the RNAi 
treatment. As a negative control (Ctrl), dsRNA against oskar, which is not expressed in 
S2 cells, was used. Protein was collected at 0, 2, and 6 hours post CHX treatment. At 6 
hours post-CHX treatment there is a modest increase in full-length SMN levels following 
Slmb RNAi as compared to the initial timepoint (0h) and as compared to control RNAi 
treatment. 
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Identification and characterization of a Slmb/B-TrCP degradation signal in SMN 
Studies of numerous UPS substrates in a variety of species have revealed the 
presence of degradation signals (called degrons) that are required for proper E3 target 
recognition and binding. Slmb/B-TrCP canonically recognizes a consensus 
DpSGXXpS/T degron, where p indicates a phosphoryl group (Jin et al. 2005; Frescas and 
Pagano 2008; Fuchs et al. 2004). There are also several known variants of this motif, for 
example: DDGFVD, SSGYFS, TSGCSS (Kim et al. 2015). As shown in Fig. 4A, we 
identified a putative Slmb/B-TrCP degron (269MSGYHT274) in the highly conserved self-
oligomerization domain (YG Box) of human SMN. Interestingly, this sequence was 
previously identified as part of a larger degron motif (268YMSGYHTGYYMEMLA282) 
that was thought to be created in SMN∆7 by SMN2 alternative splicing (Cho and 
Dreyfuss 2010). In particular, mutation of S270 (S201 in flies) to alanine was shown to 
dramatically stabilize SMN∆7 constructs in human cells, and overexpression of 
SMN∆7S270A in SMN-deficient chicken DT40 cells rescued their viability (Cho and 
Dreyfuss 2010). However, factors responsible for specifically mediating SMN∆7 
degradation have not been identified.  
In order to develop a more disease-relevant Drosophila system to investigate 
SMN YG box function, we generated a ‘vertebrate-like’ SMN construct, called vSmn 
(Fig. 4A). Transgenic flies expressing Flag-vSmn and Flag-vSmnS201A in the background 
of an SmnX7 null mutation are fully viable (Fig. S1). In fact, the eclosion frequencies of 
these animals are consistently higher than those that express Flag-SmnWT (Fig. S1). 
Additional Smn mutant constructs were generated using the vSmn backbone, including 
both the full-length (e.g. vSmnS201A) and truncated (e.g. vSmnΔ7A) versions of the 
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protein (Fig. 4A). To test the effects of overall protein length and distance of the putative 
degron from the C-terminus, we also generated vSmn constructs that are the same length 
as SMNΔ7, replacing the MEMLA* motif (the amino acids introduced by human SMN2 
splicing) with MGLRQ*, see Fig. 4A. The S201A mutation was created in this construct 
as well (MGLRQ*S201A). To mimic a constitutively phosphorylated state, we also 
introduced serine to aspartate mutations, vSmnS201D and vSmn∆7D. We transfected each 
of these constructs, Flag-tagged and driven by the native Smn promoter, into S2 cells and 
measured protein levels by western blotting (Fig. 4B). We note that these constructs are 
expressed at levels far below those of endogenous SMN protein in S2 cells; moreover, 
they do not affect levels of endogenous SMN (Fig. S2). As shown, the vSmnS201A and  
vSMNΔ7A constructs exhibited increased protein levels compared to their serine 
containing counterparts, whereas levels of the S201D mutants were reduced, suggesting 
that the phospho-degron motif identified in human SMN∆7 (Cho and Dreyfuss 2010) is 
also conserved in the fly protein. In addition to examining protein levels of each of these 
constructs in cell culture, transgenic flies expressing vSmn, vSmnS201A, vSmnΔ7S, and 
vSmnΔ7A were created. Here again, we observed that the S201A mutation increased 
protein levels of both full-length SMN and SMN∆7 (Fig. S3). 
The MGLRQ* construct is present at levels that are similar to wild-type (vSmn) 
and much higher than vSmnΔ7S. Based on the crystal structures of the SMN YG box 
(Martin et al. 2012; Gupta et al. 2015), the presence of the MGLR insertion in Drosophila 
SMN is predicted to promote self-oligomerization (A.G. Matera and G.D. Van Duyne, 
unpublished), thus stabilizing the protein within the SMN complex (Burnett et al. 2009). 
By the same logic, the relative inability of vSmnΔ7S to self-interact would be predicted 
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to lead to its destruction. To determine whether the observed increase in SMN protein 
levels correlated with its ability to interact with Slmb, we co-transfected the appropriate 
Flag-Smn constructs with Myc-Slmb in S2 cells. Protein lysates were then Flag-
immunoprecipitated and probed with anti-Myc antibody (Fig. 4C). The S201A mutation 
decreased binding of Slmb to both the full-length and the truncated SMN isoforms (Fig. 
4C). However, the vSmn∆7S construct co-precipitated the greatest amount of Slmb 
protein, despite the fact that it is present at much lower levels in the input lysate (Fig. 
4C). Because SMN∆7 is defective in self-interaction, this result suggests that the degron 
is more accessible to Slmb when SMN is monomeric and cannot efficiently oligomerize. 
SMN self-oligomerization regulates access to the Slmb degron 
To examine the connection between SMN self-oligomerization and degron 
accessibility more closely, we took advantage of two SMA patient-derived point 
mutations (Y203C and G206S) that are known to destabilize the full-length protein and to 
decrease its self-oligomerization capacity (Praveen et al. 2014). As a control, we also 
employed an SMA-causing mutation (G210V) that does not disrupt SMN self-
oligomerization (Praveen et al. 2014; Gupta et al. 2015). Next, we introduced the S201A 
degron mutation into all three of these full-length SMN constructs, transfected them into 
S2 cells and carried out western blotting (Figs. 4D and S2). The S201A degron mutation 
has a clear stabilizing effect on the G206S and Y203C constructs, as compared to the 
effect of S201A paired with G210V. Hence, we conclude that the Slmb degron is exposed 
when SMN is present predominantly as a monomer, whereas it is less accessible when 
the protein is able to form higher order multimers.  
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Figure 2.4. Identification and mutation of a putative Slmb/B-TrCP phospho-degron A. 
Identification of a conserved putative Slmb phospho-degron (DpSGXXpS/T motif 
variant) in the C-terminal self-oligomerization domain (YG Box) of SMN. The amino 
acid sequence of Smn from a variety of vertebrates is shown to illustrate conservation of 
this motif and rationale for the amino acid changes. Full-length human SMN is labeled as 
“Human” and the truncated isoform is labeled “hSMNΔ7”. Endogenous Drosophila 
melanogaster Smn is labeled “Fruitfly”. To generate a more vertebrate-like SMN, key 
amino acids in Drosophila SMN were changed to amino acids conserved in vertebrates. 
Using this SMN backbone, a serine to alanine mutation was made in the putative degron 
in both full-length (vSMNS201A) and truncated SMNΔ7 (vSMNΔ7A). An additional SMN 
construct that is the same length as SMNΔ7, but has the amino acid sequence GLRQ (the 
next amino acids in the sequence) rather than EMLA (the amino acids introduced by mis-
splicing of SMN2) was made. The same serine to alanine mutation was made in this 
construct as well (MGLRQ* and MGLRQ*S201A). Finally, to mimic a phosphorylated 
serine the full-length SMN construct (vSmnS201D) and truncated SMN (vSmnΔ7D) were 
made. B. Western blotting was used to determine protein levels of each of these SMN 
constructs, with expression driven by the endogenous promoter, in Drosophila S2 cells. 
Both the vSMN and vSMNΔ7S proteins show increased levels when the serine is mutated 
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to an alanine, indicating disruption of the normal degradation of SMN. Additionally, 
MGLRQ* protein is present at higher levels than is vSMNΔ7S and protein levels do not 
change when the serine is mutated to an alanine. Normalized fold change as compared to 
vSmn levels is indicated at the bottom. *p<0.05, **p<0.01 n=3. C. Flag-tagged SMN 
constructs were co-transfected with Myc-Slmb in Drosophila S2 cells. Protein lysates 
were Flag-immunoprecipitated and probed with anti-Myc antibody to detect SMN-Slmb 
interaction. In both full-length SMN (vSMN) and truncated SMN (vSMNΔ7), serine to 
alanine mutation decreased interaction of Slmb with SMN. Truncated SMN (vSMNΔ7) 
showed a dramatically increased interaction with Slmb as compared to full-length SMN 
(vSMN), despite the fact it is present at lower levels. D. Full-length SMN constructs 
containing point mutations known to decrease self-oligomerization (SmnY203C and 
SmnG206S) and a mutation that does not disrupt self-oligomerization in the fly (SmnG210V) 
with and without the serine to alanine mutation were transfected in Drosophila S2 cells. 
The constructs containing the serine to alanine mutation are as follows: SmnY203C-
>Smn3C-1A, SmnG206S->Smn6S-1A, SmnG210V->Smn10V-1A. The serine to alanine mutation 
has a stabilizing effect on SMN mutants with poor self-oligomerization capability. 
*p<0.05, n=3. 
 
Mutation of the Slmb degron rescues viability and locomotion defects in SMA model flies  
Next, we examined the effect of mutating the Slmb degron in the context of the 
full-length protein in vivo. We characterized adult viability, larval locomotion and SMN 
protein expression phenotypes of the G206S mutants in the presence or absence of the 
degron mutation, S201A (Fig. 5A-C). As described previously (Praveen et al. 2014), 
SmnG206S animals express very low levels of SMN and fail to develop beyond larval 
stages. In contrast, flies bearing the S201A degron mutation in addition to G206S (Smn6S-
1A) express markedly increased levels of SMN protein (Fig. 5C) and a good fraction of 
these animals complete development (Fig. 5A). Moreover, Smn6S-1A larvae display 
significantly improved locomotor activity as compared to SmnG206S or SmnX7 null mutants 
(Fig. 5B). These results strongly suggest that both the structure of the G206S mutant 
protein as well as its instability contribute to the organismal phenotype.  
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Figure 2.5. Mutation of the Slmb degron rescues defects in SMA model flies. A. 
Viability analysis of an SMA point mutation (G206S) in the presence and absence of the 
degron mutation, S201A. Flies with the following genotypes were analyzed in this 
experiment: Oregon-R (Ctrl), Flag-SmnWT,SmnX7/SmnX7 (SmnWT), Flag-
SmnG206S,SmnX7/SmnX7 (SmnG206S), Flag-SmnG206,S201A,SmnX7/SmnX7 (Smn6S-1A) or 
SmnX7/SmnX7 (SmnX7). The data for each genotype are expressed as a fraction of pupae or 
adults over the total number of starting larvae, n=200. Expression of the WT transgene 
(SmnWT) shows robust rescue of the null (SmnX7) phenotype (~68% adults). SmnG206S is a 
larval lethal mutation. In two independent recombinant lines of Smn6S-1A (Smn6S-1A1 and 
Smn6S-1A2) a fraction of the larvae complete development to become adults. B. Locomotor 
ability of early 3rd instar larvae was determined by tracking their movement for one 
minute and then calculating the velocity. To account for potential differences in larval 
size, speed is expressed as average body lengths per second moved. Genotypes are as in 
panel A. SmnG206S larvae move similarly to null animals. The motility of Smn6S-1A1 and 
Smn6S-1A2 larvae is not different from Ctrl or SmnWT larvae. ***p<0.001, n=50 to 60 
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larvae. C. Larval protein levels were examined by western blotting; genotypes as in panel 
A. Lysates from hemizygous mutant lines were probed with anti-Flag or anti-SMN 
antibodies as indicated. The slower migrating bands represent the Flag-tagged transgenic 
proteins and the faster migrating band corresponds to endogenous SMN, which is present 
only in the Ctrl (note Oregon-R has two copies Smn whereas the transgenics have only 
one). SmnG206S has very low levels of SMN protein. Flies bearing the S201A degron 
mutation in addition to G206S (Smn6S-1A) express markedly increased levels of SMN 
protein. 
 
GFP-SMN∆7 overexpression stabilizes endogenous SMN and SMN∆7 in cultured human 
cells 
Increased SMN2 copy number correlates with a milder clinical phenotype in SMA 
patients (Oskoui et al. 2016). This phenomenon was successfully modeled in mice over a 
decade ago (Monani et al. 2000; Hsieh-Li et al. 2000), showing that high copy number 
SMN2 transgenes fully rescue the null phenotype, whereas low copy transgenes do not. 
Moreover, transgenic expression of a human SMN∆7 cDNA construct in a low-copy 
SMN2 background improves survival of this severe SMA mouse model from P5 (post-
natal day 5) to P13 (Le et al. 2005). Although the truncated SMN likely retains partial 
functionality, the protective effect of SMN∆7 overexpression may not entirely be intrinsic 
to the protein. That is, SMN∆7 could also act as a ‘soak-off’ factor, titrating the 
ubiquitylation machinery and stabilizing endogenous SMN. In such a scenario, the 
prediction would be that SMN∆7A is less protective than SMN∆7S because it is not a 
very good substrate for SCFSlmb.  
We therefore compared the stabilizing effects of overexpressing GFP-tagged 
SMNΔ7S270A (SMN∆7A) and SMNΔ7 (SMN∆7S) on endogenous human SMN and 
SMN∆7. HEK 293T cells were transfected with equivalent amounts of GFP-SMN∆7A or 
-SMN∆7S. The following day, cells were harvested after treatment with cycloheximide 
(CHX) for zero to ten hours. As shown in Fig. 6A, western blotting with anti-SMN 
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showed that the SMN∆7S construct exhibits a clear advantage over SMN∆7A in its 
ability to stabilize endogenous SMN and SMN∆7. By comparing band intensities within 
a given lane, we generated average intensity ratios for each time point using replicate 
blots (Fig. 6A, table). We then calculated a ‘stabilization factor’ by taking a ratio of these 
two ratios. As shown (Fig. 6A, graph), the protective benefit of overexpressing ∆7S vs. 
∆7A at t=0 hr was roughly 3.0x for endogenous SMN∆7 and 1.75x for full-length SMN. 
Thus, as predicted above, the GFP-SMN∆7A construct was much less effective at 
stabilizing endogenous SMN isoforms. Because SMN∆7 is a relatively good SCFSlmb 
substrate, overexpression of this isoform protects full-length SMN from degradation. 
As mentioned above, experiments in an SMN-deficient chicken DT40 cell line 
showed that expression of SMNΔ7A, but not SMN∆7S, rescued cellular proliferation 
(Cho and Dreyfuss 2010). These results suggest that, when stable, SMN∆7 is intrinsically 
functional. To examine SMNΔ7A functionality in a more disease-relevant cell type, 
control and SMA induced pluripotent stem cell (iPSC) motor neuron cultures were 
transduced with lentiviral vectors expressing an mCherry control protein or SMNΔ7A 
(Fig. 6B). At 4 weeks post-differentiation, no statistical difference was observed between 
control and SMA motor neurons, however by 6 weeks, SMA motor neuron numbers had 
decreased significantly to approximately 7% of the total cell population (Fig. 6B). In 
contrast, expression of SMNΔ7A maintained motor neuron numbers to approximately the 
same level as the controls, and nearly two-fold greater than untreated cells (Fig. 6B). 
Thus expression of SMN∆7A improves survival of human iPSCs when differentiated into 
motor neuron lineages.  
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Figure 2.6. Stabilization of endogenous SMN and SMNΔ7 in cultured human cells. A. 
HEK 293T cells were transfected with equivalent amounts of GFP-SMN∆7A or -
SMN∆7S. The following day, cells were harvested after treatment with cycloheximide 
(CHX) for zero to ten hours. Western blotting with anti-SMN showed that SMN∆7S 
stabilizes endogenous SMN and SMN∆7 to a greater extent than SMN∆7A. By 
comparing band intensities within a given lane, we generated average intensity ratios for 
each time point using replicate blots. We then calculated a ‘stabilization factor’ by taking 
a ratio of these two ratios. The protective benefit of overexpressing ∆7S vs. ∆7A at t=0 hr 
was roughly 3.0x for endogenous SMN∆7 and 1.75x for full-length SMN. B. SMNΔ7A 
(S270A) expression protects SMA iPSC-derived motor neurons. Control motor neurons 
were left untreated or transduced with a lentiviral vector expressing an mCherry control. 
SMA motor neurons were left untreated, transduced with a lentiviral vector expressing an 
mCherry control, or a lentiviral vector expressing SMNΔ7A (S270A). At 4 weeks of 
differentiation, there was no difference in motor neuron survival between control and 
SMA iPSC motor neuron cultures in any of the treatment groups. However, at 6 weeks, 
SMI-32 positive motor neurons showed selective loss in SMA iPSC motor neuron 
cultures in the untreated and lenti-mCherry groups compared to control iPSC motor 
neuron cultures. In contrast, lenti-SMNΔ7A expression fully protects SMA iPSC-derived 
motor neurons. Representative images of control and SMA iPSC-derived motor neurons 
labeled with SMI-32 (green) and mCherry (red). Nuclei are stained with DAPI and shown 
in blue. *p<0.05 by ANOVA. NS = not significant. n=3 
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SMN∆7A is a protective modifier of intermediate SMA mouse phenotypes 
To examine the importance of the Slmb degron in a mammalian organismal 
system, two previously developed SMA mouse models were utilized. As mentioned 
above, the ‘Delta7’ mouse (Smn−/−;SMN2;SMNΔ7), is a model of severe SMA (Le et al. 
2005), and affected pups usually die between P10 and P18 (Avg. P15). The ‘2B/–‘ mouse 
(Smn2B/–) is a model of intermediate SMA (Bowerman et al. 2012; Rindt et al. 2015) and 
these animals survive much longer before dying, typically between P25 and P45 (Avg. 
P32). Adeno-associated virus serotype 9 (AAV9) was selected to deliver the SMN cDNA 
isoforms to these SMA mice, as this vector has previously been shown to enter and 
express in SMA-relevant tissues and can dramatically rescue the SMA phenotype when 
expressing the wild-type SMN cDNA (Foust et al. 2010; Passini et al. 2010; Valori et al. 
2010; Dominguez et al. 2011; Glascock et al. 2012).  
Delivery of AAV9-SMNΔ7A at P1 significantly extended survival in the 
intermediate 2B/– animals, resulting in 100% of the treated pups living beyond 100 days, 
similar to the results obtained with the full-length AAV9-SMN construct (Fig. 7A). In 
contrast, untreated 2B/– animals lived, on average, only 30 days. Mice treated with 
AAV9-SMNΔ7S survived an average of 45 days (Fig. 7A). Mice treated with AAV9-
SMNΔ7D, a phosphomimetic of the wild-type serine 270 residue, have an average life 
span that is equivalent or slightly shorter than that of untreated 2B/– mice (Fig. 7A). 
These results not only highlight the specificity of the S270A mutation in conferring 
efficacy to SMN∆7, but also illustrate that AAV9-mediated delivery of protein alone 
does not improve the phenotype. 
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We also analyzed the effects of SMN∆7A expression in the severe Delta7 mouse 
model (Le et al. 2005). Treatment with AAV9-SMN∆7A had only a very modest effect 
on Delta7 mice, as none of the animals (treated or untreated) survived weaning (Fig. S4). 
These findings are similar to the results in Drosophila. Transgenic expression of 
SMN∆7A in the Smn null background is not sufficient to rescue larval lethality (Fig. S3). 
Thus expression of SMN∆7A provides a clear protective benefit to the viability of 
intermediate mice, but not to severe SMA models.  
Consistent with the lifespan data, AAV9-SMNΔ7A treated 2B/– mice gained 
significantly more weight than either untreated or AAV-SMNΔ7S treated animals, nearly 
achieving the same weight as pups treated with full-length AAV-SMN (Fig. 7B). 
Treatment with full-length SMN cDNA resulted in animals that were clearly stronger and 
more mobile, consistent with the weight data (Fig. 7C). Although they did not perform as 
well as mice treated with full-length SMN cDNA, the SMNΔ7A treated animals retained 
strength and gross motor function at late time points (e.g. P100), as measured by their 
ability to splay their legs and maintain a hanging position using a modified tube-test, 
(Fig. 7C). Animals treated with AAV9-SMN∆7D and -SMN∆7S did not survive long 
enough for testing. 
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Figure 2.7. SMN∆7A is a protective modifier of intermediate SMA phenotypes in mice. 
A. Mouse genotypes include control unaffected Smn2B/+ mice, which have a wild-type 
Smn allele, Smn2B/– (2B/–) mice treated with scAAV9 expressing different versions of 
SMN, and untreated 2B/– mice, which are an intermediate mouse model of SMA. 1e11 
denotes the viral dose. scAAV9-SMN expresses full-length SMN, scAAV9-SMNΔ7 
expresses truncated SMN, scAAV9-SMNΔ7S270A expresses truncated SMN with the S to 
A change in the degron, and scAAV9-SMNΔ7S270D expresses truncated SMN with a 
phosphomimic in the degron. Delivery of AAV9-SMNΔ7A at P1 significantly extended 
survival in the intermediate 2B/– animals, resulting in 100% of the treated pups living 
beyond 100 days, similar to the results obtained with the full-length AAV9-SMN 
construct. Untreated 2B/– animals lived, on average, only 30 days. Mice treated with 
AAV9-SMNΔ7S survived an average of 45 days. Mice treated with AAV9 expressing 
SMNΔ7D had an average life span equivalent or slightly worse than that of untreated 
2B/– mice. B. Average weight (measured over time) of the animals used in panel A. 
AAV9-SMNΔ7A treated mice also gained significantly more weight than either untreated 
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or AAV-SMNΔ7S treated animals, nearly achieving the same weight as 2B/– pups 
treated with full-length SMN cDNA. C. Mouse genotypes include control unaffected 
Smn2B/+ mice, which carry a wild-type Smn allele, and 2B/– mice treated with scAAV9 
expressing different versions of SMN. scAAV9-SMN expresses full-length SMN and 
scAAV9-SMNΔ7S270A expresses truncated SMN with the S to A change in the degron. 
AAV-SMNΔ7A treated animals retained their improved strength and gross motor 
functions at late time points (P100), as measured by their ability to splay their legs and 
maintain a hanging position using a modified tube-test.  
 
SCFSlmb primarily targets unstable SMN monomers 
As indicated in Fig. 8, our findings suggest a model whereby SMN and SMN∆7 
degradation is in part mediated by SCFSlmb, a multi-component E3 ubiquitin ligase 
composed of Slmb, SkpA, Cul1, and Roc1 (Zheng et al. 2002, Jiang and Struhl 1998, 
Patton et al. 1998a; Patton et al. 1998b). Our work demonstrates that B-TrCP/Slmb binds 
directly to SMN (Fig. 2) and is one of a growing number of E3 ligases in the cell that can 
target SMN protein (Kwon et al. 2013; Han et al. 2016). SMN monomers, such as those 
created in SMNΔ7, are the primary targets for degradation. As shown in the model, 
partially-active SMNSMN∆7 dimers and active SMN oligomers are also substrates, but 
to a lesser extent. 
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Figure 2.8. Proposed model of SMN as a substrate of SCFSlmb E3 ubiquitin ligase. 
Unstable SMN monomers, such as those created in SMNΔ7, are the primary substrates 
for degradation. Active oligomers of full-length SMN (SMN-FL) and partially active 
SMN-FLSMN∆7 dimers (Praveen et al. 2014; Gupta et al. 2015) would be targeted to a 
lesser extent. SCFSlmb is a multi-component E3 ubiquitin ligase composed of Slmb, SkpA, 
Cul1, and Roc1 (see text for details). This E3 ligase complex functions together with E1 
and E2 proteins in the ubiquitin proteasome system (UPS) to tag proteins for degradation 
by linkage to ubiquitin (Ub). Phosphorylation (P) by GSK3β and/or another kinase (see 
text) is predicted to trigger ubiquitylation.   
 
Discussion 
Factors that recognize the putative SMN∆7-specific degron have not been 
identified and the molecular mechanisms governing proteasomal access to SMN and 
SMN∆7 remain unclear. In this study, we isolated factors that co-purifiy with SMN from 
Drosophila embryos that exclusively express Flag-SMN. This approach reduces potential 
bias towards SMN partner proteins that may be more abundant in a given tissue or cell 
line (Charroux et al. 1999; Meister et al. 2001; Pellizzoni et al. 2002; Kroiss et al. 2008; 
Trinkle-Mulcahy et al. 2008; Guruharsha et al. 2011). Here, we identify the SCFSlmb E3 
ubiquitin ligase complex as a novel SMN binding partner whose interaction is conserved 
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in human. Depletion of Slmb or B-TrCP by RNAi resulted in an increase in steady-state 
SMN levels in Drosophila and human cells, respectively. We also showed that ectopic 
expression of SMN∆7S270A, but not SMN∆7 or SMN∆7S270D, a phosphomimetic, is a 
protective modifier of SMA phenotypes in animal models and human iPSC cultures.  
The SCFSlmb degron is exposed by SMN2 exon skipping 
A previous study posited that a phospho-degron was specifically created by exon 
7 skipping and that this event represented a key aspect of the SMA disease mechanism 
(Cho and Dreyfuss 2010). Our identification of a putative Slmb binding site located in the 
C-terminal self-oligomerization domain of Drosophila and human SMN has allowed us 
to explore the molecular details of this hypothesis. The mutation of a conserved serine 
within the Slmb degron not only disrupted the interaction between SMN and Slmb, but 
also stabilized full-length SMN and SMN∆7. Notably, the degron mutation has a greater 
effect on SMN levels (both full-length and ∆7) when made in the context of a protein that 
does not efficiently self-oligomerize. These and other findings strongly suggest that the 
Slmb degron is uncovered when SMN is monomeric, whereas it is less accessible when 
SMN forms higher-order multimers. On the basis of these results, we conclude that 
SMN2 exon skipping does not create a potent protein degradation signal; rather, it 
exposes an existing one.  
SMN targeting by multiple E2 and E3 systems 
SMN degradation via the UPS is well-established (Chang et al. 2004; Burnett et 
al. 2009; Kwon et al. 2011). Using candidate approaches, investigators have studied other 
E3 ligases that have been reported to target SMN for degradation in cultured human cells 
(Han et al. 2016; Hsu et al. 2010; Kwon et al. 2013). Given our findings, it is therefore 
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likely that SMN is targeted by multiple E3 ubiquitin ligases, as this regulatory paradigm 
has been demonstrated for a number of proteins (e.g. p53; Jain and Barton 2010). 
Targeting of a single protein by multiple E3 ligases is thought to provide regulatory 
specificity by expressing the appropriate degradation complexes only within certain 
tissues, subcellular compartments or developmental timeframes. Moreover, ubiquitylation 
does not always result in immediate destruction of the target; differential use of ubiquitin 
lysine linkages or chain length can alter a protein’s fate (Mukhopadhyay and Riezman 
2007; Ikeda and Dikic 2008; Liu and Walters 2010). 
Avenues of future exploration include determination of the E2 proteins that 
partner with SCFSlmb as well as the types of ubiquitin lysine chain linkages they add to 
SMN. These two questions are interconnected, as ubiquitin linkage specificity is 
determined by the E2 (Ye and Rape 2009). Lysine 48 (K48) linked chains typically result 
in degradation of the targeted protein by the 26S proteasome, whereas lysine 63 (K63) 
linkage is more commonly associated with lysosomal degradation and nonproteolytic 
functions such as endocytosis (Tan et al. 2007; Kirkin et al. 2009; Lim and Lim 2010). 
Interestingly, recent work has implicated defects in endocytosis in SMA (Custer and 
Androphy 2014; Dimitriadi et al. 2016; Hosseinibarkooie et al. 2016). It remains to be 
determined how the ubiquitylation status of SMN might intersect with endocytic 
functions.  
Does SMN function as a signaling hub? 
In the Flag-SMN pulldown, we identified three E2 proteins as potential SMN 
interacting partners (Fig. 1C). Among them, Bendless (Ben) is particularly interesting. 
Ben physically interacts with TRAF6, an E3 ligase that functions together with 
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Ube2N/Ubc13/Ben in human cells (Kim and Choi 2017). TRAF6 is an activator of NF-
kB signaling, and its interaction with SMN is thought to inhibit this activity (Kim and 
Choi 2017). Notably, Ube2N/Ben heterodimerizes with Uev1a to form K63 ubiquitin 
linkages on target proteins (Ye and Rape 2009; van Wijk and Timmers 2010; Komander 
and Rape 2012; Marblestone et al. 2013; Zhang et al. 2013). Furthermore, Ben-Uev1a is 
involved in upstream activation of both JNK and IMD signaling in Drosophila (Paquette 
et al. 2010; Zhou et al. 2005). Previously, we and others have shown that JNK signaling 
is dysregulated in animal models of SMA (Garcia et al. 2013; Genabai et al. 2015; Garcia 
et al. 2016; Ahmad et al. 2016). Moreover, mutations in all three components of SCFSlmb 
lead to constitutive expression of antimicrobial peptides, which are also downstream of 
the IMD pathway (Khush et al. 2002). Together, these findings suggest the interesting 
possibility of SMN functioning as a signaling hub that links the UPS to the JNK and IMD 
pathways, all of which have been shown to be disrupted in SMA. 
Phosphorylation of the Slmb degron within SMN  
As Slmb is known to recognize phospho-degrons, one of the first questions raised 
by our study concerns the identity of the kinase(s) responsible for phosphorylating the 
degron in SMN. A prime candidate is GSK3b (Fig. 8), as this kinase recognizes a motif 
(SxxxS/T; Liu et al. 2007; Lee et al. 2013) that includes the degron and extends N-
terminally (262SxxxSxxxSxxxT274, numbering as per human SMN). In support of this 
hypothesis, we identified the Drosophila GSK3b orthologue, Shaggy (Sgg), in our SMN 
pulldowns (Fig. 1C). Moreover, GSK3b inhibitors as well as siRNA mediated 
knockdown of GSK3b were shown to increase SMN levels, primarily by stabilizing the 
protein (Makhortova et al. 2011; Chen et al. 2012). Finally, GSK3b is also responsible for 
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phosphorylation of a degron in b-catenin, a well-characterized SCFSlmb substrate (Liu et 
al. 2002). SMA mice have low levels of UBA1 (E1) ultimately leading to accumulation 
of b-catenin (Wishart et al. 2014). Pharmacological inhibition of b-catenin improved 
neuromuscular pathology in Drosophila, zebrafish, and mouse SMA models. b-catenin 
had previously been shown to regulate motor neuron differentiation and stability by 
affecting synaptic structure and function (Murase et al. 2002; Li et al. 2008; Ojeda et al. 
2011). b-catenin also regulates motor neuron differentiation by retrograde signaling from 
skeletal muscle (Li et al. 2008). The connections of UBA1 and multiple SCFSlmb 
substrates to motor neuron health thus places the UPS at the center of SMA research 
interest.  
Concluding remarks 
In summary, this study identifies conserved factors that regulate SMN stability. 
To our knowledge, this work represents the first time that SMN complexes have been 
purified in the context of an intact developing organism. Using this approach, we have 
demonstrated that the SCFSlmb E3 ligase complex interacts with a degron embedded 
within the self-oligomerization domain of SMN. Our findings establish plausible 
connections to disease-relevant cellular processes and signaling pathways. Further, they 
elucidate a model (Fig. 8) whereby accessibility of the SMN phospho-degron is regulated 
by self-multimerization, providing an elegant mechanism for balancing functional 
activity with degradation.  
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Supplementary Data 
		Genotype Pupation	(%) Eclosion	(%) 
	Flag-Smn
WT
,Smn
X7
/Smn
X7 99 73 
	Flag-vSmn,Smn
X7
/Smn
X7 86 83 
	Flag-vSmn
S201A
,Smn
X7
/Smn
X7 100 97.5 
 
Figure S2.1. Transgenic flies expressing Flag-vSmn and Flag-vSmnS201A in the 
background of an SmnX7 null mutation are fully viable. The eclosion frequencies of these 
animals are consistently higher than those that express Flag-SmnWT in the background of 
an SmnX7 null mutation. The data for each genotype are expressed as a fraction of pupae 
or adults over the total number of starting larvae, n=200.  
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Figure S2.2. A. The expression of endogenous SMN in S2 cells following transient 
transfection of either modified ‘vertebrate’ SMN constructs (vSMN and vSMNS201A) or 
Drosophila SMN constructs (SmnG210V and Smn10V-1A) is unaffected, as compared to 
mock transfection. Protein is detected by anti-Flag antibody or anti-SMN antibody as 
indicated to the left of the blots. B. Transient transfections in S2 cells express Flag-SMN 
from the endogenous promoter. Protein levels of all transfected constructs are lower than 
endogenous SMN protein levels. Protein is detected by anti-Flag antibody or anti-SMN 
antibody as indicated to the left of the blots. 
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Figure S2.3. Western blotting was used to determine protein levels of each of the SMN 
constructs, with expression driven by the endogenous promoter, in transgenic adult flies. 
Protein lysates were made by pooling 40-50 adult flies. Flies with the following 
genotypes were analyzed in this experiment: Flag-vSmn,SmnX7/Tm6b (vSmn), Flag-
vSmnS201A,SmnX7/Tm6b (vSmnS201A), Flag-vSmnΔ7S,SmnX7/Tm6b (vSmnΔ7S) or Flag-
vSmnΔ7A,SmnX7/Tm6b (vSmnΔ7A). Both the vSMN and vSMNΔ7S proteins show 
increased levels when the serine is mutated to an alanine, indicating disruption of the 
normal degradation of SMN. Flag-SMN was detected using anti-Flag antibody. 
Normalized fold change as compared to vSmn levels is indicated at the bottom. 
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Figure S2.4 Survival analysis of the effects of SMN∆7A expression in the severe Delta7 
mouse model. Genotypes include untreated SMN∆7 mice, which are a severe mouse 
model of SMA, SMN∆7 mice treated with scAAV9 expressing SMNΔ7S270A, truncated 
SMN with the S to A change in the degron, and control unaffected mice, which have a 
wild-type Smn allele.  Treatment with AAV9-SMN∆7A had only a very modest effect on 
viability and none of the animals survived weaning. 1e11 denotes the viral dose. 
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CHAPTER III: Novel SMN interaction partners related to a 
variety of cellular functions 
 
Introduction 
Spinal muscular atrophy (SMA) is a pediatric neuromuscular disorder caused by 
mutations in or loss of survival motor neuron 1 (SMN1). Approximately 95% of SMA 
patients have deletions in SMN1, and the remaining ~5% have point mutations in SMN1 
(Burghes and Beattie, 2009). The etiology of SMA remains poorly understood despite the 
progress that has been made in this field, especially therapeutically. SMN’s most well 
understood function is in the biogenesis of spliceosomal uridine-rich small nuclear 
ribonucleoproteins (snRNPs). Several putative neuron and muscle-specific functions for 
SMN have also been purported (Fan et al., 2002; McWhorter et al., 2003; Sharma et al., 
2005). Thus far, no definitive link between any function of SMN and SMA etiology has 
been shown. Moving forward, the key question in SMA research is to understand which 
function or functions of SMN are critical in causing the disease. This will be important 
for detailing the basic biology as well as refining the therapies that are currently in use. 
 In Chapter II, we showed evidence suggesting that SMN interacts with the multi-
protein E3 ubiquitin ligase, SCFSlmb. This protein complex is responsible for contributing 
to ubiquitylating SMN leading to degradation via the ubiquitin proteasome system (UPS). 
Here, we extend the analysis to examine additional SMN protein interaction partners. 
Flag-SMN was immunopurified from fly embryos, and this lysate was analysed using 
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LC-MS/MS. Here, we validate SMN interaction with three of the proteins detected at 
high levels in SMN immunopurified lysate: CG2941, Nucleosome assembly protein 1 
(Nap1), and bendless (ben). Further, we present preliminary characterization of CG2941 
including determination of cellular localization and fruit fly viability following 
knockdown of CG2941 in the whole fly as well as the other two genes present in the gene 
triplication. Therefore detection and investigation of proteins interacting with SMN in the 
developing Drosophila melanogaster embryo provide insight into the functions of SMN 
that are relevant in whole organisms early in development and therefore possibly in the 
onset of SMA. 
The protein produced from the CG2941 gene was detected in abundance from the 
Flag-immunopurified embryonic lysates. This gene is present in Drosophila 
melanogaster as a gene triplication on the X chromosome, with CG32786 and CG32783 
having a highly similar DNA sequence. At the amino acid level, this protein is not 
conserved. The protein is found only in Drosophila, and a protein with some sequence 
similarity is predicted in mosquitos. The possibility remains for conservation at the 
structural or functional levels. FlyAtlas Anatomical Expression data shows it to be most 
highly expressed in the larval central nervous system and in the adult ovary. Previously, 
CG2941 had been shown to co-purify with two other members of the SMN complex: 
Gemin2 and Gemin3 (Guruharsha et al. 2011). In humans, SMN operates as part of the 
multiprotein complex consisting of Gemins2-8 and Unrip. The fruit fly complex has been 
thought to operate as a smaller complex including SMN, Gemin2/3/5, and potentially 
Unrip. Given the available information, CG2941 is an strong candidate for acting as one 
of the Gemins not previously identified in the fruit fly SMN complex. 
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Nucleosome assembly protein (Nap1) has been associated with multiple aspects 
of chromatin remodelling and associated changes in gene expression. Nap1 works with 
SWI/SNF complexes to remodel chromatin and facilitate transcription factor binding to 
DNA (Chen et al. 1994; Cote et al. 1994; Walter et al. 1995). Nap1 preferentially 
removes and replaces the H2A-H2B histone heterodimer and its variants, thereby 
facilitating nucleosome sliding (Park et al. 2004). The expression of genes involved in 
neurulation has been shown to specifically be affected by Nap1 interaction with 
chromatin (Rogner et al. 2000). In addition to affecting gene expression through 
chromatin remodelling, Nap1 has also been suggested to directly interact with 
transcriptional activators (Asahara et al. 2002; Shikama et al. 2000; Rehtanz et al. 2004). 
Finally, it has been suggested that Nap1 may play a role in chromatin regulation, 
upstream of direct remodelling, by shuttling histones into the nucleus (Park and Luger 
2006; Mosammaprast et al. 2002). It is yet to be determined whether SMN might be 
involved in the roles of Nap1 that have previously been established, or whether they have 
a novel function separate from their individual roles. 
  Bendless (ben) was originally identified in a Drosophila melanogaster screen for 
mutations affecting the giant fiber (GF) synapse using jumping behavior as a read-out for 
such mutations (Thomas and Wyman 1984). Bendless mutants were named as such 
because they were found to have a GF neuron that failed to bend and reach it’s 
connection with the target motorneuron. Ben is highly expressed in the fruit fly nervous 
system during development and regulates synaptic connectivity by contributing to 
degradation of target proteins on the presynaptic side (Muralidhar and Thomas 1993). 
Bendless is an E2 ubiquitin conjugating enzyme that heterodimerizes with Uev1a to form 
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ubiquitin linkages on target proteins (Ye and Rape 2009; van Wijk and Timmers 2010; 
Komander and Rape 2012; Marblestone et al. 2013; Zhang et al. 2013). As SMN and Ben 
have both been suggested to affect neuronal development, this is an interesting avenue of 
further investigation. 
Experimental Procedures 
Fly stocks 
RNAi lines were obtained from the Bloomington TRIP collection. The identifying 
numbers listed on the chart are stock numbers. Each of the RNAi constructs are 
expressed from one of five VALIUM vectors and require Gal4 for expression. All stocks 
were cultured on molasses and agar at room temperature (24 ± 1°C).  
Antibodies and Western blotting 
Embryonic lysates were prepared by crushing the animals in lysis buffer (50mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 1mM EDTA, 1% NP-40) with 1X protease inhibitor 
cocktail (Invitrogen) and clearing the lysate by centrifugation at 13,000 RPM for 10 min 
at 4ºC. S2 cell lysates were prepared by suspending cells in lysis buffer (50mM Tris-HCl, 
pH 7.5, 150 mM NaCl, 1mM EDTA, 1% NP-40) with 10% glycerol and 1x protease 
inhibitor cocktail (Invitrogen) and disrupting cell membranes by pulling the suspension 
through a 25 gauge needle (Becton Dickinson). The lysate was then cleared by 
centrifugation at 13,000 RPM for 10 min at 4ºC. Cell fractionation was performed using a 
standard protocol (West et al. 2008). In brief, following centrifugation, cytoplasmic 
extracts were taken from the top 0.2mL and the nuclear pellet was resuspended in 0.2mL 
RIPA buffer. Western blotting on lysates was performed using standard protocols. Rabbit 
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anti-dSMN serum was generated by injecting rabbits with purified, full-length dSMN 
protein (Pacific Immunology Corp, CA), and was subsequently affinity purified. For 
Western blotting, dilutions of 1 in 2,500 for the affinity purified anti-dSMN, 1 in 10,000 
for monoclonal anti-FLAG (Sigma), and 1 in 500 for the Nap1 antibody (gift from M. 
Kiledijan) were used. 
Immunoprecipitation 
Lysates were incubated with Anti-FLAG antibody crosslinked to agarose beads 
(EZview Red Anti-FLAG M2 affinity gel, Sigma) for 2h-ON at 4C with rotation. The 
beads were washed with RIPA lysis buffer or three times and boiled in SDS gel-loading 
buffer. Eluted proteins were run on an SDS-PAGE for western blotting. 
Drosophila embryo protein lysate and mass spectrometry 
0-12h Drosophila embryos were collected from Oregon-R control and Flag-SMN 
flies, dechorionated, flash frozen, and stored at -80C. Embryos (approx. 1gr) were then 
homogenized on ice with a Potter tissue grinder in 5 mL of lysis buffer containing 
100mM potassium acetate, 30mM HEPES-KOH at pH 7.4, 2mM magnesium acetate, 
5mM dithiothreitol (DTT) and protease inhibitor cocktail. Lysates were centrifuged twice 
at 20000 rpm for 20min at 4C and dialyzed for 5h at 4C in Buffer D (HEPES 20mM pH 
7.9, 100mM KCl, 2.5 mM MgCl2, 20% glycerol, 0.5 mM DTT, PMSF 0.2 mM). Lysates 
were clarified again by centrifugation at 20000 rpm for 20 min at 4C. Lysates were flash 
frozen using liquid nitrogen and stored at -80C before use. Lysates were then thawed on 
ice, centrifuged at 20000 rpm for 20 min at 4C and incubated with rotation with 100 mL 
of EZview Red Anti-FLAG M2 affinity gel (Sigma) for 2h at 4C. Beads were washed a 
total of six times using buffer with KCl concentrations ranging from 100mM to 250mM 
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with rotation for 1 min at 4C in between each wash. Finally, Flag proteins were eluted 3 
consecutive times with one bed volume of elution buffer (Tris 20mM pH 8, 100 mM 
KCl, 10% glycerol, 0.5 mM DTT, PMSF 0.2 mM) containing 250ug/mL 3XFLAG 
peptide (sigma). The entire eluate was used for mass spectrometry analysis on an 
Orbitrap Velos instrument, fitted with a Thermo Easy-spray 50cm column. 
Tissue culture and transfections 
S2 cell lines were obtained from the Drosophila Genome Resource Center 
(Bloomington, IL). S2 cells were maintained in SF900 SFM (Gibco) supplemented with 
1% penicillin/streptomycin and filter sterilized. Cells were removed from the flask using 
a cell scraper and passaged to maintain a density of approximately 106-107 cells/mL. S2 
cells were transferred to filter sterilized SF900 SFM (Gibco) without antibiotics prior to 
transfection with Cellfectin II (Invitrogen). Transfections were performed according to 
Cellfectin II protocol in a final volume of 4 mL in a T-25 flask containing 107 cells that 
were plated one hour before transfection. The total amount of DNA used in transfections 
was 2.5ug. 
Immunofluorescence 
Immunofluoresce in S2 cells was performed according to the previously published 
protocol (Rogers and Rogers 2008). S2 cells were seeded onto coverslips with ConA. 
Cells were fixed in 10% formaldehyde and washed three times in PBST. Cells were 
incubated with blocking solution for 10 min at RT, then transferred to 4C with primary 
antibody (1:250 dilution) for ON incubation. Cells were washed three times in PBST and 
the secondary antibody was incubated for 1h at 4C. Following the final three washes in 
PBST, cells were mounted on microscope slides and imaged using confocal microscopy. 
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Results 
Flag-SMN interacts with proteins involved in a variety of cellular processes 
We previously generated transgenic flies that express Flag-tagged SMN proteins 
in a null Smn background, carrying a deletion of endogenous Drosophila Smn (Praveen et 
al. 2012). To preserve endogenous expression patterns, the constructs are driven by the 
native promoter and flanking sequences. We crossed hemizygous Flag-
SmnWT,SmnX7/SmnD animals to establish a stock where all of the SMN protein, including 
the maternal contribution, is Flag-tagged. Adults from this stock display no apparent 
defects and have an eclosion frequency (~90%) similar to that of wild-type (Oregon-R) 
animals.  We collected (0-12h) embryos from Flag-SMN and Oregon-R (Ctrl) animals 
and analyzed Flag-purified lysates by LC-MS/MS. In addition to the proteins described in 
Chapter II, we conducted preliminary verification experiments for three of the 396 
detected proteins (Fig 3.1 A). 
I verified the interaction of CG2941 with SMN via reciprocal co-
immunoprecipitation, demonstrating that Flag-tagged CG2941 co-purifies with 
endogenous SMN in S2 cells (Fig. 3.1 B). Nap1 was easily detectable in Flag-purified 
eluates from embryos expressing Flag-SMN and nearly undetectable in those from 
control embryos (Fig. 3.1 C). The interaction of Ben with SMN was also verified in a 
reciprocal co-immunoprecipitation, demonstrating that overexpressed Flag-tagged Ben 
co-purifies with endogenous SMN in S2 cells (Fig. 3.1 D). Cul1-Flag IP represents a low 
level of protein-protein interaction with SMN. Ben interaction with SMN is detected at 
higher levels than Cul1 interaction with SMN. Slmb interaction with SMN is a positive 
control for protein interaction with SMN, as related to the findings presented in Chapter 
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II. In S2 cells, endogenous Ben is not detected in immunoprecipitation of Flag-SMN or 
flag-tagged members of the SCF complex (data not shown). 
 
Figure 3.1. Flag-SMN immunopurified lysates contain novel interaction partners with a 
variety of cellular functions. A. Flag-purified eluates were analyzed by ‘label-free’ mass 
spectrometry. Numerous proteins that copurify with Flag-SMN are previously unknown 
interaction partners. Each of the three proteins in this table: CG2941, Nap1, and Ben are 
highly enriched in the Flag-SMN sample (SMN) as compared to the control (Ctrl). 
Numbers (x10^5) indicate intensities of peptides from each protein as detected by LC-
MS/MS. B. CG2941 interaction with SMN was verified by expressing CG2941-Flag in 
S2 cells and immunoprecipitating using Flag beads. SMN is detected in a CG2941 but 
not in the control (Ctrl) sample. SMN was detected using Drosophila SMN antibody and 
CG2941-Flag was detected using anti-Flag antibody. C. Flag purified embryonic lysates 
were probed with anti-Nap1 antibody to verify the identity of Nap1 as a protein 
interacting with SMN. No signal is detected in the Ctrl Flag-IP, but there is a clear Nap1 
band in Flag-SMN embryonic lysate. D. Ben interaction with SMN was verified by 
expressing Ben-Flag in S2 cells and immunoprecipitating lysates using Flag beads. SMN 
is detected above background (Cul1 in this blot) in Ben-Flag purified lysate. Flag-Slmb is 
a positive control for protein interaction with SMN. SMN was detected using Drosophila 
SMN antibody. 
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CG2941-Flag localizes to both the cytoplasm and nucleus 
We generated an S2 cell line that stably expresses CG2941-Flag. The S2 cells 
were cultured in media containing puromycin to maintain selection for the plasmid 
expressing CG2941-Flag. Cell fractionation was used to make protein lysates from both 
the cytoplasm and nucleus of these S2 cells. These fractions were run on a 12% gel and 
visualized using silver staining (Fig. 3.2 A). There are proteins associated with CG2941 
in both the cytoplasm and nucleus. Some bands may be common interacting proteins in 
both the cytoplasm and nucleus, whereas others are specific for each compartment. These 
lysates were also probed with anti-Flag antibody to test presence of CG2941-Flag in each 
of the eluted fractions from each cellular compartment. This served as a positive control 
for the immunoprecipitation and provides insight into CG2941 by way of knowing its 
cellular localization. 
This cell line was also used for immunofluorescence experiments (Fig. 3.2 B). S2 
cells were stained with DAPI to visualize nuclei. Anti-SMN antibody stains SMN 
predominantly in the cytoplasm as expected. SMN is present in nuclear bodies in the 
nucleus, but is not detected in all cell types. CG2941-Flag was detected using anti-Flag 
antibody. While not all cells appear to express CG2941-Flag from the plasmid, CG2941 
was present in both the nucleus and cytoplasm when it was expressed. Using a 
combination of cell fractionation and immunofluorescence, we have determined CG2941 
to be present in both the nucleus and cytoplasm of S2 cells. 
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Figure 3.2. CG2941 is in both the nucleus and the cytoplasm of S2 cells. A. S2 cells 
stably expressing CG2941-Flag under Puromycin selection contain CG2941 in both the 
cytoplasmic and nuclear cellular compartments. Cellular fractionation was used to obtain 
lysates to silver stain (top) and probe with anti-Flag antibody (bottom). Experiment 
completed by David Baillat. B. S2 cells stably expressing CG2941-Flag under Puromycin 
selection demonstrate CG2941 protein localization to both the cytoplasm and nucleus. S2 
cells were stained with DAPI to show the nucleus, anti-SMN antibody shows protein 
localization mainly to the cytoplasm, and CG2941 is in both the cytoplasm and the 
nucleus as detected by anti-Flag antibody. 
CG2941 RNAi reduces fly viability 
As the CG2941 gene and both of the genes in the gene triplication code for 
proteins of unknown function, we wanted to determine whether loss of this protein 
affected viability. There are four Bloomington TRiP lines that target one or multiple of 
the genes in the triplication (Fig. 3.3 A). Depending on the vector from which they are 
expressed, the RNAi will be present more in the soma or the germline when combined 
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with a Gal4 driver. The vectors used in the experiment include VALIUM20, which is 
effective in both the soma and the germline, and the vectors VALIUM21 and 
VALIUM22, which express well in the germline but not in the soma. 
We first expressed CG2941 RNAi from each of these fly lines using a 
ubiquitously expressed Actin5C-Gal4 driver (Fig. 3.3 B). Overall, those that expressed 
only in the germline did not affect viability. In contrast, the RNAi line that targets only 
CG2941 and not the other genes in the triplication but is expressed in the soma, decreased 
viability and the RNAi construct targeting all three genes resulted in an even greater 
decrease is fly viability. Since the RNAi lines expressed in the germline did not affect 
viability, we tested fertility in 35667 RNAi flies and found they were able to produce 
offspring. For each of the RNAi lines that were found to affect viability, we made 
observations regarding the developmental stage as which most of the flies experienced 
developmental arrest. The 53989 RNAi was found to be pharate pupal lethal and 60490 
was early pupal lethal. These differences in developmental arrest could be due to the 
differences of targeting one of the genes as opposed to targeting all three. Alternatively, 
these two RNAi lines may reduce protein levels to differing extents. 
We also expressed each of the RNAi constructs in flies using a different 
ubiquitous Gal4 driver, Tubulin-Gal4, to test whether similar effects of viability would be 
detected (Fig. 3.3 C). Again, expression of CG2941 RNAi only in the germline did not 
affect viability, but expression in the soma resulted in decreased viability. Since CG2941 
had previously been shown to be highly expressed in the larval central nervous system we 
also expressed CG2941 RNAi tissue-specifically in neurons using the Elav-Gal4 driver. 
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We did not detect any effect on fly viability in this RNAi (data not shown). This result 
suggests that CG2941 has an essential function that is not specific to neurons. 
 
Figure 3.3. CG2941 is likely an essential gene in Drosophila. A. Four different RNAi 
lines were tested for their effects on Drosophila viability. Three of the dsRNAs expressed 
in these lines were designed to specifically target CG2941 (41867, 53989, and 35667), 
whereas the fourth line (60490) is intended to target all three members of the gene 
triplication in Drosophila. The other primary distinction between these lines is that two 
are optimized for expression in the germline, while the other two are mostly expressed in 
the soma. The RNAi may be targeted to the coding sequence (CDS) or the 3’ UTR. B. 
Knockdown of CG2941 in the germline using the ubiquitous Actin5C-Gal4 driver does 
not affect Drosophila viability. In contrast, knockdown in the soma reduces adult 
viability. Blue bars indicate the expected number of adult flies based on mendelian ratios 
and green bars demonstrate the actual number of adult flies observed. C. Knockdown of 
CG2941 in the germline using the ubiquitous Tubulin-Gal4 driver does not affect 
Drosophila viability. In contrast, knockdown in the soma reduces adult viability. Blue 
and green bars represented as in panel B. 
 
Discussion 
In this work, we have described new protein interaction partners of SMN in 
Drosophila melanogaster embryos. All previous SMN interacting partners were 
originally identified using cell culture and in vitro techniques, meaning ours is the first 
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investigation of proteins in complex with SMN in an intact developing organism. This 
approach provided insight into biologically relevant interactions that occur early in 
development, the key SMA time window. The three novel interactions highlighted here 
are between SMN and CG2941, nucleosome assembly protein 1 (Nap1), and bendless 
(Ben). Each of these proteins relate to different aspects of established or suggested 
functions of SMN. By considering the cellular roles of the proteins that interact with 
SMN in early organismal development, we can generate new hypotheses about SMA 
relevant functions of SMN. 
CG2941 as a member of the core SMN complex? 
Detection of CG2941 co-purification with Gemin2 and Gemin3 (Guruharsha et al. 
2011) provided the first hint that this protein may be a member of the canonical SMN 
complex in Drosophila melanogaster. Our detection of high levels of CG2941 in Flag-
SMN purification from fly embryonic lysates, the presence of CG2941 in both the 
nucleus and cytoplasm, and suggestion of CG2941 as an essential gene all provided 
credence to this hypothesis. Lanfranco et al. (2017) recently published findings 
suggesting CG2941 as a Drosophila Gemin4 homolog in addition to identifying proteins 
with similarities to Gemin6/7/8. This suggests that Drosophila have all of the proteins 
that are present in the mammalian SMN complex, as opposed to having a smaller 
complex that carried out the same functions, as previously thought. 
The identified homologs are divergent at the amino acid level, but display 
secondary structure conservation. Additionally, they affect neuromuscular survival and 
function. CG2941 genetically interacts with Gemin3 as shown by defects in third instar 
larvae mobility, adult viability, and adult lifespan following CG2941 RNAi in a 
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hypomorphic Gemin3 mutant background (Lanfranco et al. 2017). In accordance with our 
findings, CG2941 (Gaulos) was found in complex with SMN following 
immunoprecipitation of tagged proteins from S2 cells. This study added to our findings of 
adult viability defects in flies with ubiquitous knockdown of CG2941 through 
investigation of tissue-specific effects of CG2941 RNAi in mesoderm, muscle, the central 
nervous system, and motor neurons. Each of these was found to have an effect on adult 
viability, adult lifespan, and motor function. Motor function defects were assessed using 
a climbing assay and examination of flight. 
An important next step of the investigation of CG2941 as a bona fide Gemin4 
homolog will be determination of the role of CG2941 in snRNP biogenesis; the most well 
established function of the SMN complex. This may be tested by measuring snRNA 
levels in the whole organism following CG2941 RNAi and conducting biochemical 
assays to determine the ability of CG2941 to work with the remainder of the SMN 
complex to assembly Sm proteins onto snRNAs. Since CG2941 also has similarity to 
other human proteins, as determined by bioinformatics (Lanfranco et al. 2017), 
investigation of additional functions of this protein could provide insight into alternative 
functions of the SMN complex that may have relevance in humans. Finally, since 
CG2941 is present in flies as part of a gene triplication, determination of the significance 
of the other two genes in the triplication will be important for future studies of the SMN 
complex in flies when applying that information to the SMN complex in humans. 
Chromatin remodelling and transcriptional regulation in SMA 
Nucleosome assembly protein (Nap1) has well-established roles in chromatin 
remodelling and the associated changes in gene expression. Nap1 facilitates nucleosome 
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sliding by removing and replacing the H2A-H2B histone heterodimer and its variants 
(Park et al. 2004). Nap1 may also play a role in chromatin regulation, upstream of direct 
remodelling, by shuttling histones into the nucleus (Park and Luger 2005; Mosammaprast 
et al. 2002). Especially relevant in the context of SMA, Nap1 interaction with chromatin 
affects the expression of genes involved in neurulation (Rogner et al. 2000). While SMN 
protein had not previously been known to interact with Nap1, SMN has been implicated 
in nuclear-cytoplasmic shuttling as well as neuronal development and these processes 
have been considered in relation to SMA. 
Although the primary role of SMN in cytoplasmic snRNP biogenesis is well 
studied, the connections of SMN to chromatin remodelling and regulating transcription 
involve the less understood functions of nuclear SMN. As SMN has not been suggested 
to directly affect active chromatin remodelling, SMN function with Nap1 in this cellular 
activity would be novel. SMN has been suggested to facilitate nuclear import of snRNPs, 
as part of their lifecycle involving both nuclear and cytoplasmic compartments 
(Narayanan et al. 2002; Narayanan et al. 2004). Potentially using the same or different 
nuclear import adapters, SMN works with Nap1 to shuttle histones into the nucleus. 
Several lines of evidence suggest the involvement of SMN in transcriptional regulation, 
which has the potential to relate to the protein-protein interaction of SMN with Nap1. 
Specific and general transcription factors have been shown to concentrate in nuclear 
Cajal bodies, which include SMN (Carvalho et al. 1999). Additionally, this concentration 
has been shown to be physiologically regulated, indicating the potential for functional 
significance. Transient associations of Cajal bodies with chromatin may be dependent on 
active transcription at that chromosomal locus (Platani et al. 2002). Further evidence 
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supporting the role of SMN in transcriptional regulation was provided when Zhao et al. 
(2015) demonstrated that SMN binds symmetric dimethylation of an arginine residue 
(R1810) of RNA polymerase II C-terminal domain. SMN also interacts with Senataxin 
(SETX), a helicase that unwinds R-loops around transcription termination sites (Fig. 1.5) 
(Suraweera et al. 2009), contributing to transcription termination via XRN2 exonuclease 
recruitment (Skourti-Stathaki et al. 2011). It remains an open question as to whether 
SMN and Nap1 function together in any of these contexts or whether there is simply 
overlap in their functions. The verification of their interaction provides impetus to further 
investigate this open area of research. 
SMN and cellular signalling pathways 
Previously, we and others have shown that JNK signaling is dysregulated in 
animal models of SMA (Garcia et al. 2013; Genabai et al. 2015; Garcia et al. 2016; 
Ahmad et al. 2016). Bendless (Ben) is involved in upstream activation of JNK signaling 
in Drosophila (Paquette et al. 2010; Zhou et al. 2005). This activation is accomplished 
due to Ben forming a heterodimer with Uev1a. (Ye and Rape 2009; van Wijk and 
Timmers 2010; Komander and Rape 2012; Marblestone et al. 2013; Zhang et al. 2013). 
Uev1a maintains a structural conformation that permits only K63 ubiquitin linkages on 
target proteins. K63 ubiquitin linkages are associated with formation of signaling 
complexes, rather than leading to protein degradation via the ubiquitin proteasome 
system (Ye and Rape 2009). Detecting SMN and Ben purifying together from S2 cell 
lysates suggests that Ben may be working with an E3 ubiquitin ligase to ubiquitylate 
SMN as a substrate. Alternatively, and not mutually exclusively, SMN may be regulating 
Ben activity leading to downstream effects on JNK signaling. 
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Through other protein interactions, Ben is involved in additional signaling 
pathways, such as those where NF-kB is an effector. For example, Ben has been shown to 
physically interact with TRAF6, an E3 ligase (Kim and Choi 2017). TRAF6 is an 
activator of NF-kB signaling, and its interaction with SMN is thought to inhibit this 
activity (Kim and Choi 2017). Since SMN has also been shown to interact with Ben, 
there are multiple mechanisms for regulation that may be hypothesized based on this 
interaction network. Future studies elucidating these details will be important to fully 
understanding the role of SMN in cellular signaling pathways. Together, these findings 
suggest the interesting possibility of SMN functioning as a signaling hub that is a part of 
JNK and NF-kB signaling, both of which have been shown to be disrupted in SMA. 
 
Figure 3.4. Diagram of the connections between SMN, TRAF6, and Ben-Uev1a proteins 
(Ovals) and JNK and NF-kB signaling pathways (Squares). Lines between proteins 
indicate they have been found in complex with one another. Lines connecting to signaling 
pathways show that the indicated proteins affect the activity of the cellular signaling 
pathway. In the cases where activating (arrows) or inhibitory (block line) effects are 
known, these are indicated. 
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CHAPTER IV: Conclusions and Future Directions 
 
Molecular characterization of SMN function using SMA patient mutations 
Several groups have established Drosophila as a model organism for studying 
SMA (Chan et al, 2003; Rajendra et al, 2007; Chang et al, 2008). Smn is an essential gene 
in flies and SMN’s function in snRNP biogenesis is conserved between humans and flies. 
Smn null animals have locomotor defects suggestive of neuromuscular problems (Praveen 
et al. 2012). Characterization of SMA-causing point mutations in SMN (Praveen et al. 
2014) has revealed they are similar to their human mutant counterparts on a molecular 
level. Flies carrying these mutations recapitulate the full range of phenotypic severity 
observed in SMA patients. Therefore, it is likely that pathological mechanisms that result 
in SMA are similar in flies and humans. 
As a continuation of the preliminary molecular characterization conducted in 
Praveen et al. (2014), changes in the entire proteomes of the various SMA-causing point 
mutants of SMN could be analysed. Changes in protein levels that are common to all or 
most of the point mutations are most likely to be involved in SMA etiology, considering 
all of the point mutation result in the development of SMA in patients. Changes in protein 
levels that are specific to certain point mutations or certain categories of point mutations 
(ie. protein domain or disease severity) will also be interesting. These findings will be 
related to the separation-of-function discoveries that this allelic series was intended to 
uncover. Finally, changes in protein level may be analysed in relation to other phenotypes 
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of these flies such as locomotor ability. As is a caveat with all SMA-related studies, there 
may be tissue-specific changes in protein level that are not detected using this approach. 
Additionally, changes in protein localization within cells, particularly in polarized 
neurons, will also not be detected by analysing the whole proteome from whole animals. 
In addition to examination of the entire proteome it is interesting to identify 
protein interactions with SMN. In this work, we purified wild-type SMN from Flag-Smn 
transgenic flies. This protein purification was then analysed using LC-MS/MS to identify 
the proteins that co-purified with SMN. These studies may be extended by purifying 
mutant complexes from transgenic flies and comparing and contrasting co-purifying 
proteins. We hypothesize that each of the point mutations may abrogate or reduce key 
interactions between SMN and unknown proteins. Similar to the whole proteome studies, 
SMN protein-protein interactions may be considered in terms of severity of the 
phenotype (severe, intermediate and mild) or location of the point mutation within the 
protein. As all mutations cause SMA in humans, changes in binding partners common to 
all the mutants, and that are also restored in the WT rescue flies, would be of interest in 
the context of SMA pathology. Changes in binding partners that are specific for certain 
point mutations or sets of point mutations would provide insight into the functions of 
SMN within the cell. 
The previously described experiments examining the entire proteome or SMN 
binding partners in transgenic flies should be carried out at a timepoint in fly 
development near the onset of SMA-like symptoms rather than just before death. This 
approach is most likely to provide information about the molecular happenings that cause 
SMA rather than a readout of all the problems present in a dying organism. Another 
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interesting avenue would be to examine SMN protein interaction partners over the course 
of development in a whole organism. This may be accomplished by doing Flag 
immunopurifications from lysates of transgenic flies expressing wild-type Flag-SMN at 
multiple developmental stages. A catalog of SMN protein interaction partners throughout 
development would provide insight into the functions of SMN over time. 
The most well-known function of the canonical SMN complex is its role in the 
assembly of snRNPs. The Flag-immunopurified protein lysates containing SMN 
complexes with mutant SMN could be used in snRNP assembly assays to determine the 
impact of each of the point mutations on the ability of the SMN complex to carry out 
snRNP assembly, as determined by the addition of Sm proteins to an snRNA. Since SMN 
is known to perform this snRNP assembly function in the cell, SMN may also be 
involved in biogenesis of RNPs other than splicing/spliceosomal snRNPs. Research in 
our lab has revealed that Sm proteins co-purify with specific mRNAs from Drosophila 
ovaries and S2 cells, presenting these mRNAs as potential candidates for assembly by 
SMN (Lu et al. 2014). The first step in this line of experimentation would be to determine 
whether wild-type SMN complexes are able to assemble each of these candidate RNPs. 
Following these experiments, it would be interesting to determine whether any or all of 
these RNP assembly functions were disrupted by point mutations in SMN. 
The SMN complex and protein stability 
In our preliminary isolations of the SMN complex from transgenic flies with wild-
type Flag-SMN, we identified core members of the SMN complex as well as many other 
interacting partners. Previously, Drosophila were thought to have a minimal SMN 
complex consisting of only of SMN, Gemin2, Gemin3, and rig, which is thought to likely 
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be the Gemin5 homolog (Kroiss et al. 2008). As there is now evidence that Gemin4/6/7/8 
are also present in Drosophila, any studies conducted using the fruit fly model system 
will be more directly relevant to the functions of the mammalian SMN complex than 
previously expected. We and others (Guruharsha et al. 2011; Lanfranco et al. 2017) have 
identified CG2941 as interacting with SMN. Further characterization has provided 
evidence pointing to its identity as a Gemin4 homolog in Drosophila. This additional 
characterization included demonstration of CG2941 genetic interaction with Gemin3 
using CG2941 RNAi and a hypomorphic allele of Gemin3. Gemin3 has been suggested 
to play a central role in formation of the SMN complex and SMN protein levels in the 
cell. 
Shpargel et al. (2009) reported a decrease in SMN levels in the absence of 
Gemin3 in Drosophila. Two SMA mutations in SMN (Y203C and G206S) that disrupt 
interaction with Gemin3 are known to destabilize the protein (Praveen et al. 2014). One 
possibility is that SMN degrades more quickly when it is unable to bind Gemin3. The 
Y203C and G206S mutations also display defects in self-oligomerization. This may mean 
that the instability of SMN is due to a lack of self-oligomerization. It is possible that 
proteins with these mutations fail to bind Gemin3 because of an inability to oligomerize. 
However, another SMN mutation (T205I) displays oligomerization defects, yet retains 
the ability to bind Gemin3. Thus, it is unlikely that interaction between Gemin3 and SMN 
is dependent on SMN oligomerization.  In addition, experiments with the human 
counterpart of the Y203C mutation (Y272C) show that its failure to interact with Gemin3 
is independent of its ability to oligomerize (Charroux et al, 1999). 
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Although Gemin3 binds SMN independently of SMN oligomerization status, 
Gemin3 may influence higher order oligomerization of the SMN complex. If this is the 
case, there must also be other determinants, such as the activity of E3 ubiquitin ligases, 
since overexpression of YFP-SMN in a Gemin3 mutant background in Drosophila 
restores endogenous SMN levels (Shpargel et al, 2009). This suggests that the presence 
of additional exogenous SMN has a protective effect against the degradation of 
endogenous SMN, similar to the finding in Chapter II where over expression of GFP-
SMN in human cells protected endogenous SMN. 
An investigation by Burnett et al. (2009) into the stability of SMN found a strong 
correlation between SMN stability and its incorporation into complexes. SMN that is 
unable to oligomerize has a shorter half-life than SMN that enters into a complex 
(Burnett et al., 2009). In agreement with the Drosophila studies described above, these 
investigators demonstrated that the oligomerization deficient human SMN mutations, 
Y272C, G279V and SMNΔ7, had significantly shorter half-lives than wild-type SMN. 
The experiment was conducted using human cell-based pulse-chase assays. Both Y272C 
and SMNΔ7 are known to have defects in binding Gemin3 (Charroux et al, 1999). These 
findings continue to support the idea that the defect in binding Gemin3 could be 
contributing to the instability of the Y272C and SMNΔ7 mutants in human cells. These 
studies together suggest that Gemin3 binds to SMN independent of SMN oligomerization 
status, but may still play a role in SMN stability. These findings leave open the 
possibility that defects in self-oligomerization of SMN contribute to protein stability as 
well.  
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Further characterization of the oligomerization defects using in vitro assays, and 
determination of the stability of the Y203C, G206S and T205I mutant proteins in a 
quantitative manner will help provide information about the two mechanisms proposed 
above. We can test whether Gemin3 plays a role in SMN oligomerization by determining 
whether SMN forms higher order complexes in the absence of Gemin3. Gemin3 can be 
knocked down in S2 cells and analytical ultracentrifugation can be used to obtain the 
profile of SMN complexes, and thus provide a measure of oligomerization state. A shift 
of the sedimentation profile to a lower fraction when compared to the control would 
indicate that SMN from Gemin3 knockdown cells is not incorporated into oligomeric 
complexes as well. This would suggest that Gemin3 impacts the oligomerization of SMN. 
A potential problem with this approach is that SMN is co-depleted when Gemin3 is 
knocked down. Since SMN is ubiquitylated and degraded via the proteasome (Burnett et 
al, 2009; Chapter II), the analytical ultracentrifugation assay can be performed in the 
presence of a proteasome inhibitor, such as MG132, to stabilize SMN levels. Potential 
mechanisms for Gemin3 influencing the stability of SMN are by stabilizing the 
association of Gemin2 and SMN or by contributing to masking of the Slmb degron 
(Chapter II) or another unknown degron in SMN. 
We have shown in Chapter II that SMN self-oligomerization affects the stability 
of SMN by hiding the Slmb degron that is located in the YG-box self-oligomerization 
domain of SMN. Further investigations of this topic may include a more detailed analysis 
of the precise oligomeric states of SMN where the Slmb degron is accessible and those 
where it is not.  From our findings it is unknown whether SMN dimers are sufficient to 
bury the degron and prevent ubiquitylation or whether higher order oligomers of the 
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SMN complex are required to fully protect the protein from SCFSlmb degradation. 
Additionally, studies regarding the role of other members of the SMN complex, such as 
Gemin3, in SMN ubiquitylation and degradation by SCFSlmb have not been conducted. 
The previous findings about the role of Gemin3 related to SMN stability present the 
possibility that Gemin3 is involved in regulating the accessibility of an SMN degron. 
This may be the Slmb degron as discussed in Chapter II, or another degron with an 
unidentified E3 ubiquitin ligase. 
One of the likely regulators of SCFSlmb interaction with the Slmb degron is the 
phosphorylation status of the degron. As Slmb is known to recognize phospho-degrons, 
identifying the kinase(s) responsible for phosphorylating the degron in SMN is an 
important and logical next step (Fig 4.1A). A top candidate is GSK3b (Liu et al. 2007; 
Lee et al. 2013). This kinase recognizes a motif (SxxxS/T) that includes the degron and 
extends N-terminally (262SxxxSxxxSxxxT274, numbering as per human SMN) (Fig. 4.1B). 
We identified the Drosophila GSK3b ortholog, Shaggy (Sgg), in our SMN pulldowns 
from fly embryonic lysates lending further support to the role of GSK3β in SMN 
phosphorylation (Chapter II). GSK3b-specific inhibitors and siRNA-mediated 
knockdown of GSK3b have been shown to increase SMN levels (Makhortova et al. 2011; 
Chen et al. 2012). These findings plausibly connect SMN phosphorylation to downstream 
protein degradation pathways. Finally, GSK3b is responsible for phosphorylation of a 
degron in beta-catenin, one of the most well-characterized SCFSlmb substrates (Liu et al. 
2002). This indicates the presence of a functional GSK3β kinase motif in established 
SCFSlmb substrates. 
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Figure 4.1. GSK3β is a candidate kinase for phosphorylation of the Slmb degron. A. 
SMN is degraded via the ubiquitin proteasome system. Slmb is the substrate recognition 
component of the SCFSlmb E3 ubiquitin ligase. The Slmb degron in all other known 
substrates is a phospho-degron. Preliminary evidence suggests that GSK3β is the kinase 
targeting SMN. B. GSK3β has a known target sequence in the proteins it phosphorylates. 
This amino acid sequence is found in the C-terminal YG Box of SMN and includes the 
Slmb degron (red box) and amino acids N-terminally of that sequence. 
 
The interplay between SMN oligomerization status and the presence of 
phosphorylation on the serine and threonine residues in the Slmb degron motif is not 
currently understood. One possibility is that if SMN is unable to interact with itself, the 
degron is open for kinases to phosphorylate the critical residues leading to interaction 
with SCFSlmb. Alternatively, and not mutually exclusively, the kinase may be able to 
phosphorylate the residues even when SMN is in a complex. In this case, the 
phosphorylation of the residues may lead to breakdown of the complex and subsequent 
degradation of SMN. Definitive identification of the kinase and phosphorylation of the 
predicted amino acid residues are the obvious next steps of the line of experimentation. 
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One approach would be to knockdown GSK3β in S2 cells using RNAi and harvest 
protein lysate using buffer that includes phosphatase inhibitors. This protein could be 
analyzed using Western blots to generally detect SMN phosphorylation and mass 
spectrometry to detect specific amino acids that are phosphorylated in controls and no 
longer phosphorylated following GSK3β knockdown. A potential pitfall of these 
experiments is that the C-terminus of SMN is not typically detected well using mass 
spectrometry; however, it is likely that procedures could be optimized for detection of 
these residues. Detection of the C-terminus of SMN using mass spectrometry would also 
contribute to knowledge of which lysines are ubiquitylated based on identification of 
ubiquitin conjugation sites. 
Ubiquitylation of SMN and endocytosis 
The process of protein ubiquitylation involves three main steps (Petroski 2008). 
First, an E1 protein activates ubiquitin and transfers it to the E2 enzyme. E2 proteins 
conjugate ubiquitin to their substrates. E3 proteins recognize the substrate and assist in 
the transfer of ubiquitin from the E2. In chapter II, we identified SMN as a novel 
substrate of the E3 ubiquitin ligase SCFSlmb. Future exploration of the entire process that 
results in SMN ubiquitylation includes determination of the E2 proteins that partner with 
SCFSlmb. One of the known E2 proteins to work with SCF E3 ligases is UbcD1 (Bocca et 
al. 2001). Adding to the list of known functional E2 partners of SCFSlmb would contribute 
both to knowledge of SMN biology, as well as the more general biology of the ubiquitin 
proteasome system. 
Bendless (Ben) is a candidate E2 for being involved in SMN function, as 
suggested in Chapter III. We detected Ben interaction with SMN in embryonic lysates 
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and verified this interaction using Ben-Flag overexpression and immunoprecipitation in 
S2 cells. Ben has been shown to physically interact with TRAF6, an E3 ligase, in human 
cells (Kim and Choi 2017). The possibility remains that Ben works with other E3 
ubiquitin ligases as well. We did not detect an interaction of Ben with any of the 
components of SCFSlmb in S2 cells (data not shown), but detection of physical interaction 
between E2 and E3 proteins is not always possible, even when they are known to work 
together. One way to determine the ability of Ben to work as an E2 with SCFSlmb would 
be to use in vitro ubiquitylation assays. These assays could compare the ubiquitylation 
ability of the E2 known to work with SCFSlmb (UbcD1) with that of Ben. This experiment 
is complicated due to the complex nature of SCFSlmb as a multi-protein E3 ligase, 
especially since Cul1 is activated by neddylation. Nevertheless, such an experiment 
would provide clear evidence for the ability of SCFSlmb to work with Ben (or other 
candidates) to ubiquitylate substrates. 
While ubiquitylation is most well-known in terms of protein degradation via the 
ubiquitin proteasome system, ubiquitylation does not always result in immediate 
destruction of the target. Linking ubiquitin molecules using different lysine residues and 
the presence of different chain lengths can alter a protein’s fate (Mukhopadhyay and 
Riezman 2007; Ikeda and Dikic 2008; Liu and Walters 2010). Ubiquitin linkage 
specificity is determined by the E2 (Ye and Rape 2009). Lysine 48 (K48) linked chains 
typically result in degradation of the targeted protein by the 26S proteasome, whereas 
lysine 63 (K63) linkage is generally associated with lysosomal degradation and 
nonproteolytic functions such as endocytosis (Tan et al. 2008; Kirkin et al. 2009; Lim and 
Lim 2011). Ben heterodimerizes with Uev1a to form K63 ubiquitin linkages on target 
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proteins (Ye and Rape 2009; van Wijk and Timmers 2010; Komander and Rape 2012; 
Marblestone et al. 2013; Zhang et al. 2013). Uev1a alters protein conformations to ensure 
ubiquitin linkage occurs only at K63. We also detected Uev1a in our Flag-SMN 
purifications from embryonic lysates, providing further evidence that SMN truly interacts 
with the Ben-Uev1a heterodimer in the whole organism. Considering K63 ubiquitin 
linkages are associated with functions separate from the proteasome, such as endocytosis, 
it is interesting that recent work has implicated defects in endocytosis in SMA (Custer 
and Androphy 2014; Dimitriadi et al. 2016; Hosseinibarkooie et al. 2016). 
These defects in endocytosis may be downstream effects of disruptions of SMN 
related to the ubiquitin proteasome system and SMN interactions with actin binding 
proteins. Additionally, these same disruptions directly connected to the loss of SMN may 
lead to defects in autophagy. The interconnection between autophagy and endocytosis is 
well-established (Barth and Kohler 2014). Autophagy and endocytosis share the same 
effector molecules and affect one another. Abnormal autophagy is a common feature of 
neurodegenerative diseases (Custer and Androphy 2014). Specifically in spinal muscular 
atrophy, there appears to be an accumulation of autophagosomes and their associated 
cargo in multiple different cell types. Dimitriadi et al. (2016) determined that low levels 
of SMN lead to defects in endosomal trafficking. This is believed to have the downstream 
consequence of impairing synaptic function, potentially making endocytic trafficking a 
main determinant of SMA disease pathology. Hosseinibarkooie et al. (2016) has 
conducted preliminary investigations of the molecular mechanisms underlying this 
endocytic defect in SMA (Fig. 4.2). Reduced endocytosis caused by low levels of SMN 
protein was rescued by overexpression of PLS3, a known protective modifier of SMA 
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(Oprea et al. 2008). PLS3 is an F-actin binding protein (Delanote et al. 2005) and using 
proteomic and biochemical techniques Hosseinibarkooie et al. (2016) identified another 
F-actin binding protein, CORO1C that also modifies the endocytic defects. It remains to 
be determined how the ubiquitylation status of SMN might intersect with endocytic 
functions.  
 
Figure 4.2. Increasing levels of PLS3 and CORO1C result in increased levels of F-actin 
and improved endocytic function. Endocytic function includes clathrin-mediated 
endocytosis (CME) and activity-dependent bulk endocytosis (ADBE). Figure is taken 
from Hosseinibarkooie et al, 2016. 
 
Additional functions of SMN 
A number of alternative functions for SMN in addition to its role in endocytosis 
have been put forward. Several lines of evidence have revealed connections between 
SMN and proteins involved in actin homeostasis and function (Rossoll et al, 2003; 
Shafey et al, 2005; Rajendra et al, 2007; Walker et al, 2008; Bowerman et al, 2009; 
Oprea et al, 2008). This potential role for SMN in actin cytoskeletal dynamics is closely 
related to its role in endocytosis. Numerous studies have suggested particular functions 
for SMN at the neuromuscular junction (NMJ) in mice (Kariya et al., 2008; Murray et al., 
2008; Kong et al., 2009; Michaud et al., 2010; Voigt et al., 2010; Dachs et al., 2011), 
however the extent of NMJ defects in Drosophila Smn mutants is unclear. Chan et al 
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(2003) studied Smn null mutants and observed an enlargement of boutons at the larval 
NMJ with no difference in bouton number. In contrast, Chang et al (2008) reported a 
decrease in bouton number in Smn null flies as well as high levels of SMN at the wild-
type NMJs. In other studies in the fly, nothing more than a faint accumulation of SMN at 
the NMJ has been detected (Matera lab, unpublished). One explanation for these 
discrepancies is that the NMJ defects observed by Chang et al (2008) are the result of a 
second-site mutation, since other Smn null alleles in the fly do not show NMJ defects 
(B.McCabe, personal communication). Several groups have confirmed the presence of 
NMJ defects in SMA mouse models, making the role of SMN at the NMJ in humans 
uncertain. 
Information regarding SMN protein-protein interactions may be used to inform 
previously unknown functions of SMN or to provide further evidence for suggested roles 
of SMN. Our detection of SMN interaction with nucleosome assembly protein 1 (Nap1) 
brings forth the consideration of the interplay between SMN and chromatin, as Nap1 has 
its most well-established role in chromatin remodelling. SMN has been suggested to have 
the ability to bind chromatin, specifically interacting with methylated histone H3K79 
(Sabra et al. 2013). SMN interaction with this chromatin mark was shown to affect SMN 
localization to damaged centromeres. Multiple methods were used to demonstrate 
interaction of SMN with mono- and di-methylated H3K79, although our lab was unable 
to recapitulate these results (unpublished). This may be due to a variety of reasons, 
including the use of different histone peptides in the in vitro pulldown assays. 
H3K79 methylation is known to promote transcription by enhancing transcription 
elongation (Veloso et al. 2014). Several lines of evidence suggest the involvement of 
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SMN in transcriptional regulation. Specific and general transcription factors have been 
shown to concentrate in nuclear Cajal bodies, which include SMN (Carvalho et al. 1999). 
Additionally, this concentration has been shown to be physiologically regulated, 
indicating the potential for functional significance. Transient associations of Cajal bodies 
with chromatin may be dependent on active transcription at that chromosomal locus 
(Platani et al. 2002). Further evidence supporting the role of SMN in transcriptional 
regulation was provided when Zhao et al. (2015) demonstrated that SMN binds 
symmetric dimethylation of an arginine residue (R1810) of RNA polymerase II C-
terminal domain. SMN also interacts with Senataxin (SETX), a helicase that unwinds R-
loops around transcription termination sites (Suraweera et al. 2009), contributing to 
transcription termination via XRN2 exonuclease recruitment (Skourti-Stathaki et al. 
2011). It remains an open question as to whether SMN and Nap1 function together in any 
of these contexts involving chromatin and transcriptional regulation or whether there is 
simply overlap in their functions. The verification of their interaction provides impetus to 
further investigate this open area of research. 
Role of SMN as a signaling hub 
A possible explanation for the numerous purported functions of SMN is that SMN 
works to connect different aspects of cellular signaling, both within and between distinct 
cellular processes.  For example, SMN has been shown in complex with E1 (UBA1, 
Wishart et al. 2014), E2 (Ben, Chapter III), and E3 (SCFSlmb, Chapter II; TRAF6, Kim 
and Choi 2017) proteins in the UPS. Perhaps in addition to being degraded via the UPS, 
SMN is in-turn regulating protein degradation within the cell. 
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SMN may not only be interacting with different proteins in the UPS, but may also 
be a key component in connecting the UPS with other cellular signaling pathways. The 
E2, Ben, is involved in the activation of both JNK and IMD signaling in Drosophila 
(Paquette et al. 2010; Zhou et al. 2005). Additionally, SMN interaction with TRAF6 is 
thought to inhibit the ability of TRAF6 to activate NF-kB signaling (Kim and Choi 
2017). Mutations in SCFSlmb proteins lead to constitutive expression of antimicrobial 
peptides, which are also downstream of the IMD pathway (Khush et al. 2002). The UPS, 
JNK signaling, and the IMD pathway have all been shown to be disrupted in SMA. This 
places SMN in a central role, potentially coordinating the activity of numerous processes 
within the cell. 
 
Summary 
The ultimate goal of SMA research is to discover which functions of SMN are 
most relevant to the disease in order to develop the most effective treatments. This 
discovery is important not only for SMA therapy, but also for understanding fundamental 
concepts in RNA biology and neuromuscular development. Previous research conducted 
in our lab has strongly suggested that the etiology of SMA lies in functions of SMN that 
are independent of snRNP biogenesis. To explore alternative functions and mechanisms 
of regulation of SMN we purified SMN complexes from intact, developing Drosophila 
melanogaster embryos. 
Using this approach, we have identified conserved factors that regulate SMN 
stability. This study demonstrated that the SCFSlmb E3 ligase complex interacts with a 
degron embedded within the self-oligomerization domain of SMN. Our findings suggest 
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a molecular model wherein accessibility of the SMN degron is regulated by self-
multimerization, providing an elegant mechanism for balancing functional activity with 
degradation. Additionally, we verified three novel protein interaction partners of SMN: 
CG2941, nucleosome assembly protein 1 (Nap1), and Bendless (Ben). Further 
biochemical and genetic studies related to these and other candidate proteins will provide 
insight into the physiological pathways that give rise to SMA.  
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